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Heart failure is a leading cause of morbidity and mortality in the Western world, yet the 
underlying molecular processes in the heart are incompletely understood. Calcineurin-nuclear 
factor of activated T-cell (NFAT) signaling, a central intracellular pathway in development of 
pathological hypertrophy and cardiac dysfunction, has been investigated in several projects. 
A hallmark of cardiac hypertrophy and subsequent heart failure is activation of the 
sympathetic adrenergic and the renin-angiotensin-aldosterone systems. We have identified 
that both activate specific calcineurin-dependent NFAT isoforms in neonatal murine 
cardiomyocytes (Paper I). Furthermore, we have found that all four calcineurin-dependent 
NFAT isoforms are substantially up-regulated in the myocardium of aortic stenosis patients, 
and that pressure overload-induced NFAT activation in the heart can be reversed after relief 
of the stimulus (Paper II). The role of syndecan-4, a transmembrane proteoglycan localized 
to the Z-disc of cardiomyocytes and regulated in cardiac disease, was investigated in the 
pressure-overloaded heart. Syndecan-4 was found to be essential for development of 
myocardial hypertrophy through mechanical stress-induced activation of the calcineurin-
NFAT signaling pathway (Paper III). Cardiac hypertrophy is associated with the 
neuroendocrine stress response, and in a salmonid fish model we identified a correlation 
between heart size, post-stress plasma cortisol, fibrosis and NFAT activation, emphasizing an 
evolutionary conservation of NFAT activation in cardiac disease (Paper IV). Finally, we 
have investigated a novel signaling system in the heart which has been connected to NFAT 
signaling; the reversible post-translational protein modification called O-GlcNAc. We found 
that O-GlcNAc signaling was increased in various etiologies of cardiac hypertrophy and 
failure (Paper V).  
   
8 
 
Selected abbreviations  
AB/DB aortic banding/aortic debanding 
AID  autoinhibitory domain 
ANGII  angiotensin II 
ANP  atrial natriuretic peptide  
AS  aortic stenosis 
BNP  brain natriuretic peptide  
-MHC -myosin heavy chain  
CAD  coronary artery disease 
CaM  calmodulin 
CnA/CnB calcineurin A/calcineurin B  
CsA  cyclosporin A 
ECM  extracellular matrix 
EF  ejection fraction 
ERK 1/2 extracellular signal-regulated kinase 1/2 
GAG  glycosaminoglycan 
GSK-3 glycogen synthase kinase 3 
HR/LR high-responsive/low-responsive 
JNK 2/3 jun-amino terminal kinase 2/3 
KO  knock-out 
MAPK mitogen-activated protein kinase 
MEF2  myocyte enhancer factor 2 
MI  myocardial infarction 
NE  norepinephrine 
NFAT  nuclear factor of activated T-cell  
O-GlcNAc O-linked -N-acetylglucosamine 
PTM  post-translational modification 
RAAS  renin-angiotensin-aldosterone system 
RCAN1 regulator of calcineurin 1  
SHR  spontaneously hypertensive rats 
TRPC  transient receptor potential canonical 
WKY  Wistar Kyoto rats 





Heart failure is today the leading cause of morbidity and mortality in the Western world with 
a prevalence increasing every year1-4. Estimations predict that 2-3% of the population 
translating into 23 million people worldwide are living with heart failure3, 5. Economically, 
heart failure comprises the most costly illness with health care costs twice as high as that of 
cancer6, and is now the single most common reason for adults to be admitted to the hospital in 
the United States, with a lifetime risk of one to five3, 4, 7, 8. Thus, the socioeconomic impact of 
heart failure is alarming and has epidemic proportions3, 9, 10.  
Heart failure can be defined as a syndrome in which the heart is unable to pump blood 
sufficiently to meet the requirements of the metabolizing tissues11. Thus, heart failure is not a 
single disease, but a gradually developing, final common stage of many diseases of the heart. 
Any form of heart disease can lead to heart failure which is typically caused by risk factors 
such as myocardial injury, hypertension, obesity, smoking, ischemia, diabetes, mutations, 
valvular disease, pregnancy, viral infection or toxic substances as during for instance 
chemotherapy. Age, sex and ethnicity further influence on the development of heart failure 
such that prevalence is higher in men, in elderly and in black individuals3. Due to the aging 
population and improved management of acute heart disease, the prevalence of heart failure is 
increasing although it seems that age-adjusted incidence is stabilizing and the length of 
survival after diagnosis is increasing3, 7, 12-14. Moreover, growth in both incidence and 
prevalence of heart failure is expected in the years to come as developing countries shift from 
acute to chronic cardiac disease and the pervasiveness of risk factors in these countries 
increases15, 16.    
Heart failure manifests itself as impaired cardiac function, structural alterations, 
neurohormonal activation and increased venous pressure. Patients are usually diagnosed by 
shortness of breath, edema and/or signs of inadequate tissue perfusion, e.g. fatigue, poor 
exercise tolerance and renal failure. Based on the severity of the symptoms, heart failure 
patients are grouped into four classes made by the New York Heart Association (NYHA I-
IV)17, ranging from mild to severe. Functionally, heart failure patients may be separated into 
two major groups; one with reduced ejection fraction (EF) and a large cardiac chamber (i.e. 
systolic heart failure/impaired contractility) and one with preserved EF and a small cardiac 
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chamber (i.e. diastolic heart failure/impaired relaxation). Heart failure with preserved EF is 
believed to represent more than half of heart failure cases3.  
Despite advances in management of patients and development of therapeutic strategies 
such as -adrenergic blockers and angiotensin-converting enzyme inhibitors, heart failure 
remains a deadly syndrome with 5-year mortality of 40-60%3, 7. These statistics reflect that 
the underlying disease mechanisms are poorly understood and that the important pathological 
mechanisms are not modified by present treatments modalities18, 19.  
Also for the aquaculture industry, in which millions of tons of fish are processed every 
year, myocardial remodeling, abnormalities, dysfunction and cardiac-related mortality have 
become an increasing problem20-25. Farmed fish generally grow faster than wild fish, they are 
fatter and poorer swimmers. The underlying causes of the observed pathological remodeling 
in farmed fish, however, are poorly investigated and largely unknown.  
 
Molecular mechanisms of heart failure 
Myocardial remodeling, which underlies the progressive development of clinical heart failure, 
comprises changes in mass, shape, volume and composition of the left ventricle. Molecular 
and cellular mechanisms are the main players orchestrating these changes, which encompass 
myocyte growth, myocyte death, alterations in extracellular matrix (ECM) deposition and 
fibroblast function, inflammation, alterations in myocyte energetics and changes in excitation-
contraction coupling26, 27.   
Most types of heart failure are preceded by global or regional myocardial 
hypertrophy11. Based on the Framingham Heart Study in which 5000 inhabitants of 
Framingham, Massachusetts, were followed for four decades, left ventricular hypertrophy was 
defined as an important and independent risk factor for development of heart failure and 
premature death1, 8, 28. For instance, the incidence of heart failure in men younger than 65 
years of age was increased 15-fold by presence of left ventricular hypertrophy. This is in 
contrast to the conventional belief of myocardial hypertrophy constituting an adaptive and 
compensatory mechanism to sustain the performance of the diseased heart29-33. Today, most 
evidence favors a model of both maladaptive and adaptive components of the myocardial 
hypertrophic response during remodeling in response to pathological stimuli.  
Left ventricular hypertrophy may have a concentric or eccentric morphology, causing 
either a thickening or an elongation of the cardiomyocytes and the ventricle as such, in 
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response to pressure-overload and volume-overload, respectively26, 27, 34. The defining features 
of hypertrophy in addition to increased cardiomyocyte size, are increased protein synthesis 
and increased organization of the sarcomeres, which during concentric hypertrophy are added 
in parallel, while during eccentric hypertrophy, are added in series. These changes in cellular 
phenotype are accompanied by re-introduction of the so-called fetal gene program, i.e. 
expression of genes that were active in the fetal heart. This includes a change to carbohydrate 
metabolism, induction of natriuretic peptides, isoform switching of contractile proteins such 
as myosin, actin and troponin and re-employment of developmental transcription factors35.   
At the molecular level, several intracellular signaling pathways have been identified as 
central in the ventricular remodeling process. Briefly, these include G-protein signaling, the 
main three branches of the mitogen-activated protein kinase (MAPK) cascades, protein kinase 
A (PKA) and C (PKC) signaling, glycogen synthase kinase 3 (GSK-3) and Ca2+-regulated 
pathways such as calcineurin and Ca2+/calmodulin-dependent kinase II (CaMKII)19, 26, 27, 31, 32, 
34. Z-disc proteins and membrane integrins have been proposed as essential for coupling 
mechanical signals to intracellular kinases and phosphatases in cardiomyocytes36, 37.  
Many of the aforementioned enzymes alter gene expression by communicating their 
signals to the nucleus. Five families of transcription factors have been found to co-regulate 
approximately 90% of the 10 000 expressed genes in the heart, and especially those involved 
in pathological cardiac remodeling, i.e. the GATA family, the myocyte enhancer factor 2 
(MEF2) family, the homebox family NKX, the nuclear factor of activated T-cell (NFAT) 
family and the forkhead family (FOX)38, 39. Gene expression is also regulated at the epigenetic 
level, and histone acetyl transferases (HATs) and deacetylases (HDACs) have been found to 
be central in pathological remodeling by regulating cardiac chromatin acetylation40. Recently, 
microRNAs (miRNAs), short non-coding RNAs which promote degradation of 
complementary mRNAs, have also emerged as potent regulators in cardiac disease and may 
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Calcineurin-NFAT signaling in myocardial hypertrophy and dysfunction 
Dysregulation of cardiomyocyte Ca2+ is a hallmark of cardiac disease, and several Ca2+ -
responsive signaling pathways have been causally linked to heart failure progression42. 
Calcineurin, the Ca2+-sensitive phosphatase regulating the activity of the NFAT transcription 
factor family, was first shown to be sufficient for cardiac hypertrophy by Molkentin et al. in 
199843. Later, calcineurin-NFAT has been established as a critical intracellular signaling 
pathway in pathological cardiac hypertrophy and failure43-48 (illustrated in Fig. 1).  
 
Fig. 1 Schematic of pro-hypertrophic calcineurin-NFAT signaling in cardiomyocytes. 
In normal cardiomyocytes, nuclear factor of activated T-cell (NFAT) is phosphorylated (P) and 
localized to the cytoplasm, rendering calcineurin-NFAT signaling inactive (A). In hypertrophic 
cardiomyocytes, NFAT is dephosphorylated by calcineurin and subsequently translocates to the 
nucleus and activates pro-hypertrophic, NFAT-responsive genes such as the regulator of calcineurin 1-
4 (RCAN1-4) (B).  
 
Although initially discovered in T-cells, thereof the name, almost all mammalian 
tissues express one or more isoforms of the NFAT family. In cardiomyocytes, all four NFAT 
isoforms, termed NFATc1-c4, are expressed45, 49, 50 (Fig. 2A). The characteristic feature of 
NFATc proteins that distinguishes them from other vertebrate transcription factors, is their 
ability to move rapidly into the nucleus in response to Ca2+ and calcineurin51. NFATc proteins 
contain three distinct domains: the NFAT homology region (NHR), the Rel-homology region 
(RHR) and the C-terminal domain52, 53 (Fig. 2B). The NHR is conserved between the c1-c4 
isoforms and contains a transactivating domain, a serine/threonine-rich regulatory domain to 
which calcineurin (PIxIxIT sequence) and NFAT-regulatory kinases dock and a nuclear 
localization signal. The RHR is also highly conserved between c1-c4 and is homologous with 
the Rel-domain of the nuclear factor -light-chain-enhancer of activated B cells (NF-B) 
family. It mediates DNA-binding and protein-protein interactions such as dimerization. When 
   
13 
 
NFATc proteins are dephosphorylated by calcineurin, they translocate to the nucleus and 
activate NFATc responsive genes53-56.  
 
Fig. 2 The NFATc family and 
their protein structure. 
Table of NFATc isoform 
members expressed in 
cardiomyocytes, their 
alternative names and the 
number of known human sub-
isoforms (A). Schematic 
presentation of the NFATc 
functional domains (B). NHR; 
NFAT homology region, RHR; 
Rel-homology region. The 
figure is modified from 52, 53. 
 
NFATc knock-out (KO) mice have revealed differential remodeling in response to 
various pathological stimuli depending on the isoform being experimentally modified45, 49, 57-
59, indicating an importance of analyzing the four isoforms separately in the heart. Despite 
this, their differential regulation and effects seem somewhat a mystery, as the target gene 
consensus site is the same for all isoforms53, 60. Accordingly, most studies report NFATc 
activation in a one-isoform-represents-all manner. For instance, they all activate the exon 4 
promoter of the regulator of calcineurin 1, RCAN1-4, in cardiomyocytes45, 61 (Fig. 1).  
In the human heart, 13% of the approximately 10 000 expressed genes have a 
consensus NFAT binding site in their promoter region38. In advanced stage heart failure, 
expression of 20-40% of these genes is altered, and the highest odds ratio for differential 
expression is found for genes having promoter regions with a combination of NFAT and 
MEF2 binding sites38, emphasizing the importance of NFAT signaling in cardiac pathology.  
Neurohormonal activation, in particular activation of the sympathetic nervous system 
and the renin-angiotensin-aldosterone system (RAAS), is a hallmark of cardiac hypertrophy 
and subsequent heart failure, in which norepinephrine (NE) and angiotensin II (ANGII) are 
the primary effectors mediating hypertrophic, apoptotic and fibrotic events in the heart62. 
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Although the main therapies for heart failure today aim at antagonizing the RAAS and 
adrenergic systems, the intracellular responses to ANGII and NE in cardiomyocytes are not 
completely understood. Both NE and ANGII have been shown to affect intracellular Ca2+ in 
cardiomyocytes and to activate calcineurin, indicating that they may activate one or more of 
the NFATc isoforms. However, measuring isoform-specific activation in cardiomyocytes has 
been difficult45, 49, and accordingly, little is known about endogenous cardiac NFAT isoform 
protein expression, differential regulation or their possible connection to ANGII or NE-
mediated signaling. Thus, we validated antibodies for detection of endogenous NFATc and 
phospho-NFATc proteins and investigated which isoforms were activated by ANGII and NE 
in isolated neonatal mouse cardiomyocytes (Paper I).   
Currently, although the importance of calcineurin activation has been established in 
human cardiac disease63, 64, there is little knowledge regarding NFAT isoform activation in the 
human myocardium. Activation of the NFATc4 isoform has been reported in both 
hypertrophied and end-stage failing hearts65, 66 and a c4 polymorphism correlates to left 
ventricular mass67, however it is unclear whether the other NFATc isoforms, i.e. NFATc1, 
NFATc2 and NFATc3, are activated in human cardiac disease. We therefore investigated 
expression and activation of NFATc isoforms and components of the calcineurin signaling 
cascade, such as RCAN1-4, in the hypertrophic myocardium of patients with aortic stenosis 
(AS). As AS patients are treated with surgical aortic valve replacement (AVR), we 
investigated whether relief of pressure overload in a murine model could reverse NFAT 
activation in the heart (Paper II). 
Syndecan-4 is a transmembrane proteoglycan localized to the Z-disc of 
cardiomyocytes68 and has previously been shown to be up-regulated in cardiac disease69, 70, 
and to be important for intracellular signaling in other cell types, e.g. fibroblasts and 
endothelial cells71-73. We have investigated potential syndecan-4-mediated signaling in 
cardiomyocytes, among them the calcineurin-NFAT pathway. In particular, the role of 
syndecan-4 and syndecan-4-mediated NFAT activation in development of pressure overload-
induced cardiac hypertrophy and failure was investigated in a syndecan-4 KO mouse model 
(Paper III).  
The Ca2+/calcineurin-regulated NFATc family is thought to have arisen about 500 
million years ago, producing a new group of transcription factors involved in signaling which 
is found only in the genomes of vertebrates. It has been proposed that this enabled Ca2+ 
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signals to be redirected to a new transcriptional program which provided part of the 
groundwork for vertebrate morphogenesis and organogenesis, including the cardiovascular 
system51. Thus, we investigated whether NFAT activation also occurred in a comparative 
model of cardiac hypertrophy, by measuring RCAN1-4 gene expression in hypertrophied fish 
hearts (Paper IV).  
Finally, we investigated a novel signaling system in the heart which has been 
connected to NFAT signaling in immune cells74 and hyperglycemic cardiomyocytes75; the 
reversible post-translational modification (PTM) called O-GlcNAc (O-linked -N-
acetylglucosamine), in cardiac hypertrophy and failure. Subsequent to the discovery by Torres 
and Hart76, O-GlcNAc signaling has been implicated in a diverse array of physiological and 
pathological functions in the cell77. Yet, although there is a growing recognition that O-
GlcNAc alterations are involved in cardiovascular pathophysiology in diabetes and acute 
ischemia78-81, regulation in the heart is currently not well understood. We therefore 
investigated whether O-GlcNAcylation of the cardiac proteome was altered in AS patients 
and in animal models of three common etiologies of heart failure; i.e. hypertension, 
myocardial infarction (MI) and aortic constriction (Paper V).  
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Aims of the thesis 
The overall aim of this thesis is to expand the knowledge of molecular signaling pathways 
underlying development of heart failure, particularly the role of calcineurin-NFAT signaling 
in hypertrophic and dysfunctional hearts. It is a hope that the basic knowledge that this thesis 
provides may be part of the extensive groundwork needed for understanding the underlying 
mechanisms of cardiac hypertrophy and dysfunction, a prerequisite for development of new 
therapeutic strategies for heart failure.  
 
The specific aims of the separate studies were: 
 
Paper I 
Angiotensin II and norepinephrine activate specific calcineurin-dependent NFAT 
transcription factor isoforms in cardiomyocytes 
• To validate methodology for measuring endogenous NFATc isoforms and their 
activity in cardiomyocytes. 




Calcineurin-dependent NFAT isoforms are activated in the myocardium of aortic 
stenosis patients and their activation is reversed by relief of pressure overload in a 
murine model of reverse remodeling  
• To investigate activation of the four NFATc isoforms in the pressure-
overloaded, hypertrophic myocardium of AS patients, and to assess activation 
of various components of the calcineurin-NFAT pathway in these hearts. 
• To investigate the possible reversal of cardiac NFAT activation following relief 










Syndecan-4 is essential for development of concentric myocardial hypertrophy via 
stretch-induced activation of the calcineurin-NFAT pathway  
• To investigate the role of syndecan-4 in pressure overload-induced 
development of cardiac hypertrophy and failure using a syndecan-4 KO mouse 
model. 
• To investigate the role of syndecan-4 in regulation of the calcineurin-NFAT 
signaling pathway during cardiac hypertrophy and failure.  
• To investigate the role of syndecan-4 in mechanical stress-induced activation 
of NFAT in cardiomyocytes.  
 
Paper IV 
Cortisol response to stress is associated with myocardial remodeling in salmonid fishes  
• To investigate the influence of stress-induced plasma cortisol on cardiac 
hypertrophy in salmonid fish. 
• To investigate NFAT activation in neuroendocrine stress-induced cardiac 
hypertrophy in fish. 
 
Paper V 
Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure 
• To investigate the regulation of O-GlcNAcylation of cardiac proteins in various 
etiologies of cardiac hypertrophy and failure; in AS patients and in models of 
hypertension, MI and aortic constriction in rat.      








The findings in this thesis result from molecular biology techniques employed on tissue and 
cells from human patients and animal models of cardiac disease such as mice, rats and fish. 
We have performed in vivo animal experiments, obtained myocardial biopsies per-operatively 
from patients, and employed cell lines and primary cell cultures for various in vitro 
experiments. In this section, methodological considerations of central experiments will be 
discussed.   
 
Human myocardial biopsies        
To study molecular signaling in human heart disease directly, we have utilized myocardial 
biopsy tissue taken during open heart surgery (Fig. 3). More specifically, our transmural 
biopsies were obtained from the left ventricle of patients with severe, symptomatic AS during 
elective AVR, and from a non-ischemic area of patients undergoing coronary artery bypass 
graft (CABG) operation due to coronary artery disease (CAD). Alternatively, we could have 
used tissue from explanted hearts yielding considerably more tissue, however, the explanted 
hearts represent severe, end-stage heart failure, and not hypertrophy in-transition-to failure, 
which is the case for AS hearts undergoing AVR. Thus, myocardial tissue from AS patients is 
more suitable for studying signaling pathways underlying the progressive development of 
failure in the human heart. In both cases, the main limitations concern ethical and 
experimental restrictions and a restricted number of samples, not to mention the control tissue, 
which can not be obtained from healthy controls.  
 
 
Fig. 3 Human myocardial biopsy. 
Myocardial biopsy from a patient taken  
per-operatively using a biopsy needle.  
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Animal models of cardiac disease 
To allow for in vivo gain and loss-of-function studies, genetically modified mouse models are 
extensively used in basic cardiac research. To study the role of a specific protein, the gene is 
overexpressed or knocked-out in the whole mouse or in the heart specifically, and it can even 
be controlled conditionally. In our studies, we have investigated the role of syndecan-4 in vivo 
in the pressure-overloaded hearts of mice lacking syndecan-4 in all cells82. We have also 
employed neonatal cardiomyocytes from syndecan-4 KO mice, NFAT-luciferase reporter 
mice47 and syndecan-4 KO-NFAT-luciferase reporter mice (generated in our laboratory for 
Paper III). This approach is limited by the fact that the genetic modification is non-natural, it 
may influence on development and thus not be suited to study adult cardiac disease, and one 
might study phenotypes caused by off-target effects. However, these genetically modified 
mice are widely used by the cardiac research community and constitute a powerful tool to 
study the role of a specific protein in cardiac disease.  
To mimic human cardiac diseases, in vivo animal models are well established and 
widely used in the field of basic cardiac research. In our project, we have employed 
spontaneously hypertensive rats (SHR), a model of MI made by ligation of a coronary artery, 
and a model of AS made by aortic banding (AB; Fig. 4), in mice and rats. These experiments 
are limited by the shortcomings of these models in resembling the human disease, the 
reproducibility of the models and also by species/line differences, sex and diet. Importantly, 
the relative age of the animals used is younger than that of the human patients, and as many 
disease-related processes are age-dependent, this constitutes a limitation to studies such as 
ours. Nevertheless, the coronary artery ligation and AB models have been shown to be valid 
models of myocardial remodeling following infarction and of concentric hypertrophy, 
respectively83. To study aspects of reverse left ventricular remodeling such as seen after AVR 
in AS patients84-86, we have employed a mouse model where AB is followed by aortic 
debanding (DB)87-89. To control for effects of the operation itself, experiments were 
accompanied by sham-operated control animals. SHR develop increased blood pressure from 
the age of five to six weeks and progressive cardiac hypertrophy from the age of 20 weeks, 
and have been widely used as a model of cardiac remodeling following hypertension90. 
Normotensive Wistar-Kyoto (WKY) rats were included as controls for this study.  













Fig. 4 Left ventricle and lungs of sham-operated and aortic-banded mice. 
Wild type mouse (A), lungs and left ventricles following sham operation (left) and aortic banding 
(AB; right) (B). Scale bar: 1 cm. Photo: Ida G. Lunde.  
 
The studies in salmonid fish were performed on hearts from a genetic model of 
cortisol stress-responsiveness, in two lines of rainbow trout (Oncorhynchus mykiss) selected 
for high and low post-stress plasma cortisol levels (HR and LR, respectively)91. In our study, 
these lines provided a tool to study cardiac effects of transiently elevated plasma cortisol 
levels. However, as the HR and LR fish have been bred for several generations during the 
selection regime, mutations and random genetic drift could have accounted for the observed 
effects. This is, however, unlikely as our findings were confirmed in a wild salmonid 
population (Salmo trutta; European brown trout) (Fig. 5). As stress and cardiac disease are 
both major problems in the fish farming industry20-23, the HR and LR lines may actually be of 























Fig. 5 European brown trout (Salmo trutta) and its heart.  
European brown trout (A) and its heart, showing the single atrium, the single ventricle,  
the aorta and the bulbus (B). Photo: Lars-Petter Skillestad and Ida G. Lunde.  
 
Cardiomyocyte cell cultures 
As cardiomyocytes are terminally differentiated, primary cell cultures have been the most 
commonly used cell system in the field. Although techniques for cardiomyocyte isolation 
were developed 35 years ago92, isolation of high quality/high yield cultures remains somewhat 
of an art and often unpredictable difficulties occur, limiting the experiments93. When studying 
signaling in cardiomyocytes, cells isolated from neonatal mice and rats have been preferred, 
as these survive in culture for a longer period than adult cells, and have a greater potential for 
morphological changes. Thus, we have employed primary cultures of neonatal 
cardiomyocytes to a large extent in our studies (Fig. 6). Although there are obvious 
shortcomings of using neonatal rodent cardiomyocytes to model what is happening in adult 
human cardiomyocytes in the intact heart during disease, many of the molecules found to be 
involved in hypertrophy and failure in vitro have been confirmed in vivo94. For instance, 
cyclic mechanical stretching of neonatal cardiomyocytes, such as performed in our studies 
(Papers II-III), have been shown to induce hypertrophy and expression of genes in a way 
similar to in vivo pressure overload95. As an alternative to transfection, cultured 
cardiomyocytes can be treated with arginine-tagged, cell permeable peptides such as the 
syndecan-4-derived peptides we used in Paper III96.  Thus, neonatal cardiomyocytes represent 
a useful in vitro tool in basic cardiac research to study direct effects on cardiomyocytes.  












Fig. 6 Neonatal mouse and cultured primary neonatal cardiomyocytes.  
Neonatal mouse (A) and cultured primary cardiomyocytes stained for nuclei in blue and                  
actin filaments in red (B).  Photo: Lars-Petter Skillestad and Geir Florholmen/Ida G. Lunde.  
 
General techniques to study cardiac dimensions and function  
To assess the state of cardiac hypertrophy and dysfunction, post-mortem analyses, 
echocardiography and left ventricular catheterization were performed to measure cardiac 
dimensions, hemodynamics and function in mice and rats. Standard patient management 
including echocardiography was performed in human patients. In fish, cardiac dimensions 
were assessed by post-mortem measurements. Expression of commonly used cardiac marker 
genes associated with hypertrophy and failure such as atrial natriuretic peptide (ANP), brain 
natriuretic peptide (BNP), -myosin heavy chain (-MHC) and -skeletal actin (Acta1) were 
assessed by reverse transcription real-time polymerase chain reaction (RT-PCR) from 
myocardial tissue of humans, rodents and fish. These methods are detailed in the individual 
papers.  
 
General molecular biology techniques  
We have employed numerous molecular biology techniques and among them, the most central 
are summarized briefly in this section. For quantitative gene expression analyses, RT-PCR 
was performed. For protein and phospho-protein analyses, immunoblotting (i.e. Western 
blotting) and immunohistochemistry were performed. Luciferase activity was measured as a 
reporter of NFAT activation. General histochemistry and microscopy were performed to study 
tissue morphology. To study protein interactions, immunoprecipitations from tissue and in 
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vitro pull down and overlay peptide array techniques were employed. Overexpression of 
proteins was obtained by transfection using plasmid vectors, and primary cardiomyocytes 
were treated with cell-permeable peptides. To study protein synthesis in cells, incorporation 
of radioactive leucine was assessed. To validate antibody specificity, peptide arrays and 
blocking peptides were used. These methods are detailed in the individual papers.  
 
Molecular techniques to study cardiac NFAT activity 
NFAT mRNA, protein and phosphorylation status 
Measuring endogenous cardiac NFATc isoform-specific activation has been difficult 
especially due to low antibody specificity45, 49 and extensive alternative splicing resulting in 
numerous sub-isoforms97. Accordingly, little is known about their protein levels or their 
differential regulation in the heart. In Paper I we evaluated antibodies for doing so in isolated, 
neonatal murine cardiomyocytes. Thus, we evaluated antibody specificity and identified 
NFAT isoform protein bands by immunoblotting in combination with antibody blocking 
peptides in order to measure the level of phosphorylated, i.e. inactive NFATc, and the non-
phosphorylated/total NFATc protein. In Paper II, we further validated their specificity by 
overexpressing NFATc1-c4 in human endothelial kidney 293 (HEK 293) cells, and employed 
the validated antibodies to detect NFATc1-c4 and phopsho-NFATc1-c4 in the human 
myocardium. In Paper III, we used these antibodies to detect activation of NFATc4 in murine 
myocardium and cells. Although there are limitations regarding non-specific protein bands, 
we believe we have identified antibodies that can be used to detect endogenous cardiac 
NFATc isoforms specifically in myocardial tissue from mice and humans (Papers I-III). We 
also believe that the phospho-NFAT antibodies can be used to detect isoform activation, at 
least during acute stimulation or short-term remodeling. As shown in Paper II, chronic 
remodeling such as in the myocardium of AS patients, phospho-levels become difficult to 
interpret as the proteins themselves are highly regulated, perhaps representing sub-isoform 
expression97 and PTMs other than phosphorylation. 
NFAT isoform mRNA measurements constitute another approach to assess isoform 
specificity and activation, however increased NFAT isoform protein levels do not correlate to 
increased NFAT mRNA (Paper II). As it has been proposed that NFAT expression in T-cells 
is regulated by proteolysis, and only partially at the transcriptional level98, we do not believe 
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that measuring NFAT isoform mRNA should be used alone to describe NFAT isoform 
activity in the heart (Paper II).  
 
NFAT target gene expression 
Proteins within the RCAN family (also called modulatory calcineurin-interacting protein 1 
(MCIP1), adapt 78, calcipressin 1 or down syndrome critical region 1 (DSCR1)) bind and 
inhibit calcineurin activity99. The human RCAN1 gene comprises seven exons, the first four 
of which are alternative first exons, resulting in different isoforms with specific expression 
patterns and regulation. Exons 1 + 5-7 give rise to RCAN isoform 1-1, while exons 4 + 5-7 
give rise to RCAN1-4100. Expression of the exon 4 isoform, RCAN1-4, has been shown to be 
extremely sensitive to calcineurin activity in vivo61, 101. RCAN1-4 is a direct NFATc target in 
the heart due to a dense cluster of 15 consensus binding sites for NFAT in the exon 4 
promoter61, 102, 103. Thus, RCAN1-4 transcript level, as well as protein level, have been used in 
numerous studies as a sensitive indicator of changes in calcineurin-NFAT activity. However, 
as there are no yet known differences in consensus target site for the NFATc isoforms45, 53, 60, 
61, this method of evaluating calcineurin-NFAT activity is not NFAT isoform-specific. 
RCAN1-4 can be used to measure both exogenous and endogenous NFAT activation in the 
heart, and have in our studies been measured by RT-PCR and immunoblotting in human and 
murine cardiac tissue, as well as in fish (Papers II-IV).  
 
NFAT reporter systems 
NFAT-luciferase reporter constructs and transgenic mice provide yet another sensitive 
method for measuring NFAT activity. NFAT-luciferase mice47 have nine copies of an NFAT 
binding site from the interleukin (IL)-4 promoter (5`-TGGAAAATT-3`) inserted upstream of 
the luciferase gene. Thus, luciferase activity serves as a reporter of NFAT activity. This model 
has been widely employed for in vivo studies in combination with other genetically modified 
mouse models, and provides a relatively easy method for evaluating calcineurin-NFAT 
activity, although not providing information regarding NFATc isoform activation. In our 
studies, we have employed cardiomyocytes from neonatal NFAT-luciferase mice to 
investigate the regulation of calcineurin-NFAT signaling by ANGII, NE and several 
syndecan-4-derived cell-permeable peptides (Papers I and III). To measure syndecan-4-
mediated NFAT activation in vivo, we generated syndecan-4 KO-NFAT-luciferase reporter 
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mice in our laboratory (Paper III). Furthermore, we employed the NFAT-luciferase mice to 
investigate reversal of NFAT activation following relief of pressure overload (Paper II).  
Recently, a red fluorescent protein (RFP)-based reporter assay to measure NFAT 
activity was introduced by Rinne and Blatter104. This new tool allows for continuous 
monitoring by fluorescence microscopy of transcriptional NFAT activity in living cells, 
contrasting the more traditional luciferase assay which requires cell lysis and substrate 
addition. However, the RFP-assay requires transfection into cardiomyocytes as genetically 
modified mice have not yet been made, and for our studies, we have not used this method.  
 
Intracellular NFAT translocation 
The nuclear-cytoplasmic ratio of NFAT reflects the summation of nuclear import and export 
rates. Fusion constructs of NFATc proteins and green fluorescent protein (GFP) have been 
used in numerous studies of NFAT activation in living cells by measuring translocation 
between the cytoplasm and nucleus. Although isoform-specific, they do not provide a method 
for measuring endogenous NFATc activity as they require transfection into cardiomyocytes. 
In Paper II, we have fused NFATc1-c4 to enhanced GFP (EGFP) in expression vectors, and 
transfected these into HEK 293 cells, routinely done by lipofection, in order to validate 
antibody specificity. We have not, however, used these expression vectors in cardiomyocytes 
to quantitate NFATc translocation.  
 In order to measure endogenous NFATc isoform activation by translocation, 
subcellular protein fractionation can be performed. Thus, we measured the amount of NFATc 
found in the cytoplasmic and nuclear fractions in cardiomyocytes and HEK 293 cells 
following ANGII or NE stimulation and syndecan-4 transfection, respectively (Papers I and 
III), using the NFATc antibodies validated in Paper I.  
 
NFAT DNA binding 
Other molecular techniques to study NFAT activation in cardiomyocytes include NFAT-
binding to the consensus target DNA sequence, which can be measured for instance by using 
the Transcription Factor Assay Kit available for NFATc1 from TransAm (Active Motif 
Europe, Belgium), which we used in Paper I, or electrophoretic mobility shift assays 
(EMSA)/gel shift assays. Moreover, chromatin immunoprecipitation (ChIP) could also be 
performed for this purpose. All these methods are antibody-dependent, and thus require 
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specific NFATc antibodies. As discussed in Paper I, we were successful in applying the 
NFATc1 Transcription Factor Assay Kit mentioned above to measure nuclear NFATc4 
activation in murine hearts using the antibodies that we validated. However, the kit was not 
compatible, in our hands, with the small yield of nuclear protein from neonatal 
cardiomyocytes in combination with the c2, c3 and c4 antibodies.  
 
Protein interactions 
Calcineurin-NFAT signaling can be activated through protein-protein interactions. For 
instance, as we found that NFAT signaling was altered in syndecan-4 KO hearts, we 
investigated the potential regulation of cardiac calcineurin-NFAT signaling by direct 
interaction between syndecan-4 and calcineurin (Paper III). Similarly, it was recently shown 
that the Ca2+- and integrin-binding protein 1 (CIB1) binds directly to the regulatory 
calcineurin B subunit (CnB) in the heart, anchoring calcineurin to the sarcolemma and 
regulating its catalytic activity towards NFAT105. Such an activation of calcineurin has 
previously also been shown for the muscle LIM protein (MLP) which anchors calcineurin to 
the Z-disc and regulates NFAT activation106. Thus, calcineurin-NFAT protein interactions can 
also reflect NFAT activation in the heart.  
 
Calcineurin activity 
In assessment of cardiac NFAT activation, studying the activity of phosphatases and kinases 
regulating level of NFAT phosphorylation are relevant approaches. Especially, calcineurin 
activation reflects the level of NFAT activation. The active calcineurin comprises the catalytic 
calcineurin A subunit (CnA) and the two Ca2+-binding regulatory proteins, CnB and 
calmodulin (CaM). When activated by Ca2+, CnB and CaM bind to CnA, displacing the 
autoinhibitory domain (AID) and rendering calcineurin in an active conformation allowing 
access of substrates, such as NFATc, to the catalytic domain107. Thus, immunoprecipitations 
of CnA revealing CnB and/or CaM binding, and the tissue levels of CnA, CnB and CaM, 
serve as indications of calcineurin activity. In Paper II, we measured the levels of these three 
proteins in the hearts of AS patients to assess NFAT activation level. Also commonly used to 
determine the relevance of calcineurin activity in a process are inhibitors of calcineurin 
activity, such as cyclosporine A (CsA), FK506108, 109 and the NFAT-derived peptide 
VIVIT110. To this end, we used CsA to measure calcineurin-dependent NFAT activation in 
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neonatal NFAT-luciferase cardiomyocytes in Paper I. Finally, biochemical assays employing 
the phosphorylated regulatory subunit II (RII) of PKA as substrate, the most efficient and 
selective substrate known for calcineurin are used in numerous studies to assess calcineurin 
activity (e.g. Calcineurin Cellular Activity Assay Kit, Calbiochem).  
 
GSK-3 activity 
GSK-3 has been shown to promote nuclear export and thus inactivation of NFATc 
transcription factors by serine/threonine phosphorylation, antagonizing calcineurin action and 
development of cardiac hypertrophy111, 112. Serine 9 phosphorylation by Akt (also called 
protein kinase B (PKB)) in the phosphatidylinositol 3-kinase (PI3-K) pathway113 has been 
found to inhibit GSK-3  activity111. Thus, increased levels of GSK-3 phosphorylation 
indirectly suggest increased NFATc activity. We have measured the level of GSK-3 and its 
phosphorylation level in myocardial tissue from AS patients and in syndecan-4 KO hearts as a 
means of approaching the mechanisms behind NFAT activation (Papers II-III). Furthermore, 
we have measured Akt phosphorylation (i.e. activation) as an indication of GSK-3 
inactivation, and thus indirectly of NFAT activation.  
 
MAPK activity 
It has been shown that each of the three main branches of MAPK signaling cascades, i.e. the 
extracellular signal-regulated kinase 1/2 (ERK 1/2), p38-MAPK and jun-amino terminal 
kinase 2/3 (JNK 2/3), directly modulate calcineurin-NFAT signaling in the heart114. ERK 1/2 
is believed to activate NFATc4 in cardiac myocytes and T-cells114-116. JNK and p38, on the 
other hand, directly phosphorylate NFAT, inhibit nuclear translocation, and thereby 
antagonize calcineurin-dependent NFAT activation and hypertrophy114. Thus, the protein and 
phosphorylation levels of these kinases (i.e. activation) could serve as indirect indications of 
NFAT activity in the heart. In Papers II-III we approached the level of NFAT activation 
indirectly by measuring protein levels and phosphorylation of ERK1/2, p38 and JNK 2/3.  
 
NFAT dimerization partners 
Investigating the level of, interaction with and activity of NFAT dimerization partners are 
useful approaches to further assess the degree of NFAT activation indirectly. NFATc proteins 
bind DNA weakly and it has thus been proposed that they need a partner protein to 
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transactivate genes117. For instance, NFATc proteins are known to transactivate target genes 
in heterodimers with MEF2, AP-1 and GATA426, 117, in addition to forming NFAT 
homodimers118. We investigated the levels of MEF2, AP-1 and GATA4 in Paper II to 
indirectly approach NFAT activation in the myocardium of AS patients. 
 
Upstream activators of NFAT signaling; TRPC channels 
Ca2+ function is likely compartmentalized into microdomains in cardiomyocytes since the 
substantial alterations in intracellular Ca2+ during contraction-relaxation do not trigger Ca2+ -
dependent signaling such as NFAT. One important intracellular pool of Ca2+ is generated by 
Ca2+ influx into the cell through transient receptor potential canonical (TRPC) channels in the 
sarcolemma26. These are store-operated, i.e. their opening is coupled to a decline in SR Ca2+ 
stores, and they are believed to play an important role in development of hypertrophy119, 120. 
Importantly, of the seven family members, TRPC1, 3 and 6 are known to influence Ca2+-
dependent calcineurin-NFAT activity121-124. Thus, assessing the level of these three TRPC 
channels and their activity is yet another approach to indirectly describe NFAT activation 
level in the heart. We measured the level of TRPC 1, 3 and 6 in the biopsies from AS patients 
(Paper II).  
 
Ethical considerations 
The central ethical considerations of the projects constituting this thesis concern utilizing 
tissue from patients and experiments on animals. The human myocardial biopsy protocol was 
approved by the Norwegian regional ethics committee and conformed to the Declaration of 
Helsinki. Importantly, informed written consent was obtained from each patient included. 
Experiments on mice and rats were approved by the Norwegian National Animal Research 
Committee and conformed to the Guide for the Care and Use of Laboratory Animals (NIH 
publication No. 85-23, revised 1996, US). The transport and study procedures of fish were 
reviewed and approved by the Norwegian Food Safety Authority (www.mattilsynet.no) and 
the Norwegian National Animal Research Committee, respectively, while the fish studies 
performed in Bosnia and Herzegovina were approved by the State Veterinary Office of 
Bosnia and Herzegovina (http://www.vet.gov.ba). Certainly, care was taken to reduce, replace 
and refine (RRR) when employing animals in our studies.  
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Summary of results 
The main results from this thesis are summarized briefly in this section.  
 
Paper I 
Angiotensin II and norepinephrine activate specific calcineurin-dependent NFAT 
transcription factor isoforms in cardiomyocytes 
We identified antibodies for specific detection of endogenous NFATc isoforms and their 
phosphorylation level in cardiomyocytes. This was accomplished by validating antibody 
specificity towards murine NFATc isoforms by immunoblotting using isoform-specific 
peptide arrays and antibody peptide inhibitors. Both ANGII and NE increased calcineurin-
dependent NFAT activation when measuring NFAT-luciferase activity, and they both 
stimulated hypertrophy of neonatal cardiomyocytes as assed by radioactive leucine 
incorporation. More specifically, we showed that both ANGII and NE activated NFATc1 and 
c4 in cardiomyocytes, while NFATc2 was activated by NE. Neither ANGII nor NE activated 
NFATc3 in cardiomyocytes. These results show that ANGII and NE, so central in the 
development of cardiac hypertrophy and failure, activate specific NFATc isoforms in 
cardiomyocytes, suggesting that mechanisms exist for NFATc isoform-specific activation in 
these cells.   
 
Paper II 
Calcineurin-dependent NFAT isoforms are activated in the myocardium of aortic 
stenosis patients and their activation is reversed by relief of pressure overload in a 
murine model of reverse remodeling  
Using the antibodies for NFATc detection validated in Paper I on human myocardial biopsies, 
we showed substantially increased protein levels of all four NFATc isoforms in left 
ventricular tissue from AS patients. Despite increased protein levels, we found no difference 
in NFATc1-c4 mRNA between AS patients and controls, suggesting post-transcriptional 
regulation of NFATc isoforms in the diseased human heart. RCAN1-4 mRNA and protein 
were significantly increased, as expected, indicating increased NFATc activity in AS, 
although a substantial fraction of NFAT remained phosphorylated. We also showed regulated 
activity and protein level of GSK-3, Akt and the MAPKs modulating calcineurin-NFAT 
activity, p38, ERK 1/2 and JNK 2/3, as well as increased levels of NFAT interaction partners 
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AP-1, MEF2 and GATA4, and of the NFAT-activating TRPC channels, in AS. Our results on 
the regulation of NFATc protein, mRNA and phosphorylation were confirmed in the murine 
AB model. Collectively, these results show multi-leveled activation of calcineurin-NFAT 
signaling in AS and substantially increased protein levels of the four calcineurin-dependent 
NFATc isoforms, suggesting that all four play a role in development of hypertrophy in the 
human heart. Moreover, a murine AB-DB model mimicking AVR in AS patients, relieving 
the pressure overload, showed that NFAT activation could be reversed, suggesting that the 
detrimental effects of this pathway in the diseased heart may be a target of pharmacological or 
surgical intervention.  
 
Paper III 
Syndecan-4 is essential for development of concentric myocardial hypertrophy via 
stretch-induced activation of the calcineurin-NFAT pathway  
We showed that syndecan-4 KO mice do not develop concentric hypertrophy after AB, as do 
wild type mice, but rather show signs of cardiac dilation, dysfunction and failure. In 
agreement with lack of hypertrophy, syndecan-4 KO cardiomyocytes exhibited no increase in 
width following AB, as seen in wild type cells. Syndecan-4 KO mice showed reduced 
calcineurin-NFATc4 activation following AB, and cardiomyocytes lacking syndecan-4 
showed minimal activation of NFAT following cyclic mechanical stretch. We identified that 
calcineurin bound directly to the intracellular part of syndecan-4 through its AID when 
syndecan-4 was dephosphorylated at serine 179. Experiments assessing NFAT activation 
suggested that the binding of calcineurin to the cytoplasmic part of syndecan-4 activated 
calcineurin. We found increased levels of syndecan-4 mRNA and protein in the hypertrophic 
myocardium of AS patients, and showed that overexpression of the membrane-localized 
syndecan-4 in cells activated NFATc4. Finally, we showed that syndecan-4 was 
dephosphorylated after AB in mice and in myocardial tissue from AS patients, favoring 
calcineurin-NFAT activation. Altogether, these results suggest that syndecan-4 is essential for 
development of concentric hypertrophy in the pressure-overloaded heart by activating the 
calcineurin-NFATc4 pathway.  
 
 




Cortisol response to stress is associated with myocardial remodeling in salmonid fishes 
We found that fish responding to stress with high plasma cortisol (HR line and wild 
salmonids) had bigger hearts than fish responding with low plasma cortisol (LR line and wild 
salmonids). HR hearts showed signs of hypertrophy of the outer, compact layer of the 
ventricle and increased focal fibrosis and collagen expression, indicating pathological cardiac 
remodeling. We showed increased RCAN expression in the HR hearts, suggesting increased 
NFAT activity in hearts of fish responding to stress with high levels of plasma cortisol. These 
results indicate that the cortisol response to stress is associated with pathological remodeling 




Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure 
We observed increased levels of O-GlcNAcylation of numerous cardiac proteins in 
myocardial tissue from AS patients and rat models of chronic heart disease including 
hypertension, MI and aortic constriction. O-GlcNAc levels were increased in both 
hypertrophied and failing hearts. We showed increased levels of the enzymes regulating the 
O-GlcNAc PTM, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), in pressure-
overloaded hearts, yet not in hearts post-MI. Pharmacological inhibition of OGA, increasing 
O-GlcNAc, reduced contractility in muscle strips from post-MI failing hearts, suggesting that 
O-GlcNAcylation is a possible mediator of cardiac dysfunction. Our results support the novel 
concept that O-GlcNAc signaling is involved in development of cardiac hypertrophy and 
failure of various etiologies, and to our knowledge, we were the first to show regulation of 
this PTM in the hypertrophic human heart.  




In the following, some specific and central topics from this thesis will be discussed.  
 
The four NFATc isoforms in the heart – functional specification or redundancy? 
The NFAT protein was discovered in 1988125 as a nuclear protein regulating the IL-2 
promoter in activated T-cells. The four genes encoding the four calcineurin-dependent 
NFATc isoforms are thought to have arisen 500 million years ago in the vertebrate genome51, 
54, and it is now evident that almost every cell type expresses at least one NFATc family 
member53, 54, 56, 117. Murine cardiomyocytes express all four45, 49, 50, and in Paper II we show 
that all of them are expressed and up-regulated in the human hypertrophic myocardium. 
Extensive alternative splicing of the NFATc genes further complicates the picture, predicting 
for instance as much as 24 different NFATc4 sub-isoforms97. Thus, to understand the 
functional specification or redundancy of the NFATc isoforms is a particular challenge. 
In non-cardiac tissues, murine KO models of single NFAT isoforms have revealed 
mild phenotypes suggesting relatively overlapping functions56. Given the central role of 
NFAT in gene regulation in the heart, it is interesting that the pathological significance of 
removing each individual member to the development of cardiac hypertrophy, is varied. This 
implies that although they are usually reported in a one-isoform-represents-all manner, we 
believe that NFATc isoforms should be analyzed separately in the heart as they probably have 
specific functions.  
Lack of NFATc1 is embryonically lethal with defects in the cardiac septum and valves 
resembling common congenital heart defects seen in the human population57, 58, and thus has 
not been investigated in the adult heart. Mice lacking NFATc2, on the other hand, are viable, 
and do not develop calcineurin-dependent hypertrophy and heart failure49. Likewise, NFATc3 
null mice demonstrate a significantly reduced hypertrophic response following diverse 
stimuli59. Somewhat surprisingly, NFATc4 KO mice do not show a compromised ability to 
undergo hypertrophic growth45, 59, although overexpression of NFATc4 induces extensive 
hypertrophy43. NFATc4 has also previously been shown to be activated in human heart 
failure65, 66 and there is a c4 polymorphism which correlates to left ventricular mass of 
humans67. Collectively, these results point towards functional specification of the NFATc 
isoforms in cardiac remodeling.  
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Nevertheless, their differential regulation and effects are mysterious. The consensus 
target site53, 60 and the DNA-binding domain (within the RHR) are highly conserved among 
all isoforms51 such that they all activate RCAN1-4 and BNP in cardiomyocytes45, 61. Our 
finding that all four isoforms are up-regulated in the myocardium of AS patients could also 
imply co-regulation of the NFATc isoforms (Paper II).   
In Paper I we show that ANGII and NE activate NFATc in an isoform-specific manner 
in murine cardiomyocytes, which is in line with the findings of Rinne et al.126, 127. These 
authors show isoform-specific activation in atrial and ventricular myocytes, and also indicate 
tissue-specific NFATc regulation within the heart127. Interestingly, it was recently shown that 
NFATc4, but not c2 and c3, is a direct target for the anti-hypertrophic miR-133 in the heart, 
suggesting activation of an NFATc isoform-specific mechanism in development of heart 
failure128. In skeletal muscle, a closely related tissue where all four  isoforms are expressed, 
specific NFATc proteins show nuclear localization at specific developmental stages129. 
Furthermore, specific combinations of the isoforms determine transcription of fiber type-
specific genes130. Interestingly, NFAT isoforms were found to be differentially sensitive to 
Ca2+ transients elicited by electrical activity. Differences in export/import mechanisms for the 
c1 and c3 isoforms have also been shown in skeletal muscle131 as well as in 
cardiomyocytes126, 127. Collectively, these results suggest that cellular mechanisms exist for 
functional specification of NFAT isoforms in tissues where all four NFATcs are expressed, 
such as the myocardium. This strengthens our hypothesis that these four should be analyzed 
separately during cardiac remodeling.  
NFATc-DNA binding is relatively weak such that they need a dimerization partner to 
transactivate genes. Some degree of isoform-specificity has been suggested to be product of 
their associated nuclear partners, despite the RHR being highly conserved among the c1-c4 
isoforms53, 117. For instance in skeletal muscle it was shown that GATA bound NFATc1 but 
not c2132. Furthermore, NFAT isoforms may be localized to different intracellular pools and 
thus activated by local Ca2+ signals. It was noted by Rinne and co-workers that NFATc3 
particularly accumulated around the nucleus in non-stimulated cardiomyocytes127. Moreover, 
the various isoforms may have a different sensitivity towards Ca2+ and calcineurin such as 
seen in skeletal muscle130. Yet another possibility is that calcineurin and other NFAT-
modifying enzymes are localized to specific subcellular domains through association with 
binding proteins. For instance, calsarcins are localized to the sarcomere where they bind 
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calcineurin133. Interestingly, we (Paper III) and others106 show that syndecan-4 and MLP, 
respectively, which are localized to the Z-disc, also bind calcineurin and affect NFATc4 
activation.  
Of notice, more pronounced effects are seen when several NFATc genes are lacking53, 
however generation of mice lacking all isoforms have failed due to lethality45. For instance, 
mice lacking both c3 and c4 show embryonic lethality and a thin ventricle with reduced 
myocyte proliferation134. Interestingly, these embryos could be rescued by re-expression of 
constitutively active NFATc4, further complicating our present attempt to understand the 
functional relationship between NFATc members.  
In conclusion, mechanisms for isoform-specific regulation of calcineurin-dependent 
NFAT isoforms exist in cells expressing more than one of the NFAT genes, such as 
cardiomyocytes expressing all four. Expression of these four genes over 500 million years of 
evolution point to functional specificity, along with differential expression in various cell 
types and at various developmental stages, and interestingly, the pathological significance in 
the heart of removing each member individually, varies. Nevertheless, there is evidence for 
overlapping functions such that they all regulate the same disease-related genes in the heart, 
and are co-regulated themselves in the hypertrophic human heart.  
 
Is calcineurin-NFAT signaling a therapeutic target in heart failure? 
Although it was not the purpose of the work constituting this thesis, the ultimate aim of our 
research is to improve basic knowledge such that therapy for heart failure may be improved. I 
will therefore discuss the current standing of calcineurin-NFAT modulation in heart disease. 
Heart failure therapy has over the last 40 years moved from bedrest to diuretics, inotropes, 
vasodilators, renin-angiotensin-aldosterone inhibitors and -blockers which slow, but not 
reverse, the progression18. Today, several lines of evidence indicate that any degree of 
hypertrophy is detrimental for cardiac function and survival30, suggesting benefits from 
inhibition of hypertrophy. Although several therapies that improve outcome are associated 
with a regression of hypertrophy135-138, few clinical therapies target hypertrophic remodeling 
directly today.  
The naturally occurring and widely used immunosuppressive drugs CsA and FK506 
inhibit calcineurin109. Early animal studies showed that CsA/FK506 could inhibit and reverse 
hypertrophy following pressure overload, infarction, hypertension, adrenergic stimulation and 
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genetic modification43, 139-144. Thus, it is generally accepted that inhibition of calcineurin can 
reduce development of pathological hypertrophy, making calcineurin-NFAT intervention 
promising.  
Despite these results, some studies have reported that lack of hypertrophy following 
pathological stimuli may result in failure and premature death. Accordingly, it was shown that 
although CsA attenuated pressure overload hypertrophy, at the same time it enhanced the 
susceptibility to failure145. This resembles our finding from mice lacking syndecan-4 in which 
pressure overload-induced concentric hypertrophy was inhibited, but at the same time, 
dysfunction and failure was induced (Paper III).  
Supplying to the extensive evidence showing that calcineurin-NFAT is activated in the 
hypertrophic heart, we show that all NFATc isoforms are substantially up-regulated in the 
hearts of AS patients (Paper II). Since calcineurin-NFAT studies have relied heavily on 
murine models in which genetic manipulations have been initiated before birth, little was until 
recently known about the reversibility of this system, which is relevant for instance for our 
AS patients undergoing AVR. Berry et al. engineered mice with an inducible, constitutively 
active calcineurin gene in cardiomyocytes146. Activation of calcineurin in adulthood triggered 
pathological hypertrophy preceding systolic dysfunction, fetal gene activation, fibrosis and 
clinical heart failure. Interestingly, cardiac hypertrophy and fetal gene expression reversed 
when calcineurin activity was turned off, although fibrosis only partially reversed. 
Furthermore, these authors showed that systolic dysfunction is second to hypertrophy and not 
vice versa, supporting the view that hypertrophy itself could be a target for therapy. Along 
these lines, we show that NFAT activation induced by AB in mice is reversed when the 
pressure overload is relieved by DB (Paper II), suggesting that it is possible to 
pharmacologically or surgically reverse the pathological calcineurin-NFAT signals in the 
heart. Furthermore, extrapolating from these results, it is likely that some of the deleterious 
effects of calcineurin-NFAT signaling in the AS hearts are reversed when treated with AVR. 
To inhibit the calcineurin-NFAT system in the heart, various approaches other than 
employing FK506/CsA are possible. For instance, the VIVIT peptide inhibits NFAT signaling 
directly110, 147, or inhibition can be based on natural calcineurin blockers such as RCAN1, 
cain/cabin-1 and A-kinase anchor protein 79 (AKAP79) which directly bind calcineurin, or on 
enzymes that regulate nuclear export of NFAT such as GSK-3, MAPKs and the dual-
specificity tyrosine kinase 1a (Dyrk1a)56, 117. Thus, based on current literature, it is not 
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unlikely that inhibition of calcineurin-NFAT will be a therapeutic option in the future, 
targeting the pathological hypertrophic response.  
 
Is syndecan-4 a mechanosensor in cardiomyocytes and does it play a role in development 
of heart failure? 
The transmembrane proteoglycans, among them the syndecans, were discovered 30 years 
ago148 and it is now evident that all animal cells express one or more of the less than ten 
known transmembrane proteoglycans149. Invertebrates express one syndecan, reflecting a long 
evolutionary history, and two rounds of duplication produced the four vertebrate isoforms, 
namely syndecan-1-4. The extracellular cleavage domain and the attachment sites for heparan 
sulfate glycosaminoglycan (GAG) chains, the transmembrane domain and the cytoplasmic 
domain are highly conserved among species, reflecting a conserved function. Mice lacking 
syndecans are viable and fertile, and phenotypes different from wild type appear when 
subjecting them to postnatal stress or injury. Syndecans have been implicated in a variety of 
biological functions spanning from regulation of cell adhesion, growth factor signaling and 
cell migration to metabolism. In particular, they function as co-receptors in these processes.  
External load per se plays a critical role in determining cardiac muscle mass. Although 
it is well known that mechanical forces influence on cardiomyocyte function and structure, 
little is known about how mechanical stimuli are converted into intracellular signals. 
Syndecan-4 (illustrated in Fig. 7) is expressed in focal adhesions in many cell types, and in 
cardiomyocytes it has been localized to the Z-disc and costamere68. The Z-disc constitutes a 
physical anchor for myofilaments, the cytoskeleton, receptors and transmittors of mechanical 
signals37. Thus, Z-disc protein complexes have been proposed to be an essential part of the 
stretch-sensing apparatus in cardiomyocytes36.  
Fig. 7 The proteoglycan syndecan-4.  
The transmembrane proteoglycan syndecan-4 is 
localized to the cardiomyocyte Z-disc, and consists 
of an extracellular domain with attached 
glycosaminoglycan (GAG) chains and a cleavage 
site for shedding of this domain. The cytoplasmic 
domain of 28 amino acids consists of two 
conserved regions (C1/C2) and the syndecan-4-
specific V-region. Serine 179 is indicated.  
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Due to its localization and connectivity to both the ECM and the cytoskeleton, we 
propose a role for syndecan-4 as a transducer of mechanical stimuli in cardiomyocytes. This is 
based on our findings in Paper III showing 1) no development of concentric hypertrophy nor 
increase in cardiomyocyte width of pressure-overloaded syndecan-4 KO hearts, 2) a 
correspondingly reduced NFAT activation, 3) minimal calcineurin-NFAT activation in 
syndecan-4 KO cardiomyocytes subjected to cyclic mechanical stretch, and 4) increased 
syndecan-4 levels in pressure-overloaded human hearts. Interestingly, a role for syndecan-4 as 
a mechanotransducer in fibroblasts has also been hypothesized by others150.  
It has previously been suggested that mechanical stimuli converge on integrins151, 152, 
transmembrane receptors that bind to the ECM and activate intracellular signaling pathways 
instructing cytoskeletal organization and gene expression. As syndecan-4 is a co-receptor for 
1 integrin149, 153, its role as a mechanosensor in cardiomyocytes may be through integrin 
interaction. 
Interestingly, syndecans carry 3-5 heparan sulfate GAG chains extracellularly which 
are known to bind ligands such as growth factors, the ECM, cytokines, chemokines and 
pathogens. Heparan sulfate as a GAG is essential for animal life154, and although this aspect 
has not been studied in this thesis, syndecan GAG chain function is likely to be relevant also 
for the heart due to levels of both ligands and syndecan being altered in cardiac disease.  
The extracellular core protein also associates with proteases resulting in cleavage and 
shedding of the extracellular part. Increased shedding has been linked to wound repair, 
inflammation, tumor progression and cell stress149, 155. Indeed, although it was a small study 
of 76 patients, syndecan-4 in the serum was recently identified as a novel biomarker for 
patients with chronic heart failure156, reflecting that yet another aspect of syndecan function is 
relevant for human heart disease. Interestingly, syndecan-4 serum levels correlated with LV 
geometry parameters such as mass, and correlated negatively to EF. Thus this aspect of 
syndecan-4 function may represent a biomarker of ventricular remodeling.  
Syndecans have the ability to signal through their small cytoplasmic domain, 
especially to the cytoskeleton, and they are linked to PDZ-domain protein networks. The 28 
amino acid cytoplasmic domain, very similar in zebrafish and up to humans157, and absolutely 
conserved between mammals158, consists of the C1 and C2 domains, similar in syndecan 1-4, 
with the isoform-specific V-region separating the two conserved domains. Thus, the V-region 
of syndecan-4 is expected to play a distinct role. Although syndecans lack intrinsic kinase 
   
38 
 
activity, they are involved in signaling by directly interacting with signaling molecules. In 
fibroblasts, syndecan-4 regulates localization, activity and stability of PKC through a direct 
interaction with the V-region71, 159. In Paper III, we identified that the V-region contains a 
PIxIxIT-similar motif, a motif found in other calcineurin-binding proteins such as NFAT147, 
AKAP160 and RCAN1101, 103, and that calcineurin bound directly to the V-C2 region. 
Furthermore, we found that syndecan-4 without its extracellular domain activated NFAT, 
emphasizing the importance of the cytoplasmic domain in syndecan-mediated signaling. 
Thus, we identified a molecular mechanism likely to underlie the inhibited development of 
concentric hypertrophy and reduced NFAT activation in mechanically stretched syndecan-4 
KO cardiomyocytes.    
Phosphorylation of serine 179 (pS179) within the C1 region of syndecan-4 has been 
shown to constitute a molecular switch regulating the function of the cytoplasmic part. pS179 
negatively regulates higher-order oligomerization, PKC binding and activity, binding of 
syntenin, cell mobility and growth by altering the conformation of the cytoplasmic tail72, 161-
164. In Paper III, we found that pS179 also negatively regulated the interaction with 
calcineurin, and the level of pS179 was reduced in pressure-overloaded murine and human 
hearts, favoring binding of calcineurin to syndecan-4. The only known kinase responsible for 
regulating pS179 is PKC165, and until now, no phosphatase has been shown to regulate this 
site. We speculate based on our findings that calcineurin itself may dephosphorylate S179 in 
the heart (Paper III). 
 As discussed above, syndecan-4 KO mice did not develop concentric hypertrophy 
following pressure overload, but rather developed cardiac dilatation and failure. Although our 
data clearly indicate syndecan-4-mediated, pro-hypertrophic NFAT activation in 
cardiomyocytes, syndecan-4 may also mediate other effects in the heart that contribute to the 
premature failure compared to wild type. This may be related to other non-investigated 
signaling pathways such as those involved in the inflammatory response as well as non-
cardiomyocyte effects related to the ECM and development of fibrosis. In a very recent study, 
syndecan-4 KO mice were shown to have impaired cardiac function and increased mortality 
due to ruptures following MI69. Lack of syndecan-4 was associated with a reduced 
inflammatory reaction, impaired fibroblast conversion to myofibroblasts and reduced ECM 
deposition in the infarct region after MI. Thus, this study indicates a protective role of 
syndecan-4 in remodeling of the infarct region. In a parallel study, however, cardiac function 
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was found to be improved in mice lacking syndecan-4 following MI82. Interestingly, 
hypertrophy in the infarct border zone with a concomitant increase in NFAT activation was 
increased in syndecan-4 KO mice after infarction. This suggests that additional layers of 
complexity are present in syndecan-4-mediated cardiac remodeling and NFAT activation, and 
that syndecan-4 function in the heart may vary whether it is related to global pressure-
overload or regional remodeling following an infarct.  
 In conclusion, our study and recent literature suggest that syndecan-4 is involved in 
cardiac remodeling and dysfunction following pressure-overload and MI, regulating central 
aspects such as hypertrophy, inflammation and fibrosis. Due to its cellular localization and 
binding of both extra-and intracellular molecules, it is likely that syndecan-4 transmits 
mechanical stimuli in pressure-overloaded and mechanically stressed cardiomyocytes. 
Furthermore, it is likely that several aspects of syndecan-4 function such as extracellular GAG 
chain interactions and shedding, as well as intracellular signaling, are relevant for heart 
disease.  
 
Does O-GlcNAc play a role in development of heart failure and does it affect 
calcineurin-NFAT signaling? 
Of the annotated human cardiac proteins, 62% have a known PTM, and approximately 25% 
have more than one type of PTM, according to current literature166, 167. PTMs define the 
functional and structural plasticity of proteins in eukaryotes as well as prokaryotes, they 
modulate protein activity and interactions in fundamental molecular processes and they 
represent disease- and tissue-specific modifications. The most studied PTMs are perhaps 
phosphorylation cascades, the histone code of acetylation and methylation, ubiquitination and 
glycosylation168. Glycosylation can either be N-linked and irreversible as in proteoglycans 
such as syndecan-4, or O-linked (O-GlcNAc), with dynamics comparable to 
phosphorylation169.  
Subsequent to the discovery in 198476, O-GlcNAc signaling has been implicated in a 
diverse array of physiological and pathological functions in the cell77 and although O-GlcNAc 
alterations are now believed to be involved in cardiovascular pathophysiology78-81, regulation 
and function in the heart are currently not well understood. O-GlcNAcylation encompasses 
nuclear, cytoplasmic and mitochondrial proteins of nearly all functional classes77, 170-173 and is 
achieved by the two highly conserved enzymes, OGT and OGA. OGT deletion is 
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embryonically lethal suggesting O-GlcNAc as a PTM to be essential for life174 and to date, 
OGT has been found in all tissues examined169. In brain and spinal cord, proteomic analyses 
have identified nearly a thousand O-GlcNAcylated proteins175.  
In hypertrophic and failing hearts, a shift towards a more glycolytic metabolism 
occurs176-180, suggesting that more substrate for glycosylation is available in the failing heart. 
Accordingly, in Paper V we found upregulated levels of O-GlcNAc signaling and the cycling 
enzymes in hypertrophic and failing myocardium of various etiologies, i.e. chronic 
hypertension, aortic constriction and MI. Functionally, the consequences of the observed 
increase in cardiac O-GlcNAcylation may be of importance to the failure progression. 
Numerous studies have shown that during acute ischemic and hypoxic stress, O-GlcNAc 
mediates cardioprotection78-81, 181-185. Severe injury such as trauma-hemorrhagic shock induces 
O-GlcNAc in the heart, and increasing O-GlcNAc levels during resuscitation improve cardiac 
recovery and reduce inflammation in rodents173, 186. Recently, the role of O-GlcNAcylation in 
post-MI failure was addressed by deletion of OGT in the adult mouse heart187. These mice 
showed exacerbated dysfunction after MI, indicating a cardioprotective effect of protein O-
GlcNAcylation following MI. Thus, these studies indicate that O-GlcNAcylation can be 
cardioprotective against stresses such as ischemia and hypovolemic shock.  
Interestingly, O-GlcNAcylation was recently assessed in the  physiologically 
hypertrophied hearts of swim-exercised mice, and found to be down-regulated188, suggesting 
that our finding of increased O-cardiac GlcNAcylation in the chronically diseased heart is part 
of a pathological mechanism. Moreover, our finding of increased O-GlcNAcylation in non-
failing hypertrophic ventricles suggests that increased O-GlcNAc may be a cellular 
mechanism preceding development of failure (Paper V).  
When chronically increased, O-GlcNAcylation contributes to cardiovascular 
dysfunction, such as seen in diabetes79, 169. In cardiomyocytes from diabetic mice, reducing 
protein O-GlcNAc levels improve contractile function189, while hyperglycemia, mimicking 
diabetes by increasing O-GlcNAc levels, impairs cardiomyocyte Ca2+ cycling190. Moreover, 
cardiomyocytes from hyperglycemic, diabetic rats exhibit impaired relaxation191. 
Interestingly, we found that pharmacological inhibition of OGA, increasing O-GlcNAc, 
decreased the contractility of post-MI failing hearts, suggesting that chronic O-GlcNAcylation 
promotes cardiac dysfunction (Paper V). As several proteins such as PLN192, actin, myosin 
heavy chain, myosin light chain and troponin I193 are known to be O-GlcNAcylated, it seems 
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reasonable to assume that the reduced function could be related to altered activity of several 
of these key contractile proteins.  
Another interesting aspect of O-GlcNAc signaling concerns the interplay with protein 
phosphorylation (Fig. 8). O-GlcNAc cycles on serine/threonine residues of proteins with a 
timescale, distribution and abundance similar to phosphorylation, and there is an extensive 
crosstalk with phosphorylation cascades79, 169, 194-199. OGT and OGA are activated by both O-
GlcNAcylation and phosphorylation and in many cases, OGT, OGA, kinases and 
phosphatases are found in the same complexes195, 199. Actually, all known O-GlcNAcylated 
proteins are also phospho-proteins. When phosphorylation of 700 sites was determined after 
increasing O-GlcNAc with an OGA inhibitor, phosphorylation of virtually all actively cycling 
sites was either increased or decreased196.  
Fig. 8 Crosstalk between protein O-linked 
phosphorylation and glycosylation.  
A multi-enzymatic complex of OGT, OGA, 
kinases and phosphatases (PP) (A) regulates the 
dynamic, serine/threonine protein modifications of 
phosphorylation (P) and O-GlcNAc (G) (B). From 
the top; a naked protein, an O-GlcNAcylated 
protein, a phosphorylated protein and a protein 
modified by both. The figure is modified from199.  
 
Since we observed a relatively high number of proteins being O-GlcNAcylated in the 
heart (Paper V), crosstalk with phosphorylation is likely also important in cardiac remodeling. 
Furthermore, results from studies in which serine/threonine residues have been mutated have 
been accepted as evidence for the importance of phosphorylation without considering O-
GlcNAcylation. In view of this, PTMs might need re-evaluation considering also O-
GlcNAcylation of specific residues.  
O-GlcNAc signaling has been linked to NFAT activity in immune cells74, 200. It was 
demonstrated that OGT is central in lymphocyte activation and IL-2 production through 
regulation of NFAT. Interestingly, NFAT was O-GlcNAcylated following direct binding to 
OGT and O-GlcNAcylation likely regulated nuclear translocation of NFAT. Since OGT and 
OGA often are found in the same complexes as enzymes regulating phosphorylation, 
interaction with calcineurin and for instance GSK-3 could be novel mechanisms for NFAT 
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regulation. Thus, interaction between O-GlcNAc and NFAT signaling is something that 
probably will be investigated in the heart in the near future, by us or others. Furthermore, the 
maturing of proteomic analysis will probably reveal more details concerning the role of O-
GlcNAc in heart disease and the specific proteins involved167.  
 
Is pathological cardiac remodeling in fish induced by the cortisol stress response? 
The fish heart demonstrates a high degree of anatomical and physiological plasticity in 
response to stimuli such as sexual maturation and environmental changes such as temperature, 
hypoxia and food availability201. In salmonids, the ventricle consists of an outer compact layer 
of circumferentially arranged, spindle-like cardiomyocytes and an inner spongy 
myocardium202. Plastic changes involve hyperplasia and hypertrophy of both layers201. For 
example, salmonids undergo cardiac hypertrophy as a routine remodeling mechanism during 
cold acclimation203.    
Millions of tons of fish are processed every year in the aquaculture industry, and 
cardiac-related mortality has become a costly problem20-25, 204, 205. Wild salmonids are 
characterized as very athletic and can migrate thousands of kilometers202, however when 
farmed, they generally grow faster, are fat and become poor swimmers. The ventricle of 
farmed salmonids is often more rounded, in contrast to the pyramidal structure of wild fish, 
with fat depositions, coronary arteriosclerosis and malformations201. When raised under 
identical conditions, cardiac function does not differ between wild and farmed fish206, 
indicating that there are other underlying causes of the observed pathological remodeling in 
farmed fish than genetics.  
In humans, severe stress is associated with a poor prognosis for individuals with 
cardiac disease207, 208. High cortisol responsiveness to stress is associated with increased 
cardiovascular mortality209 and serum cortisol is a predictor of cardiac events in patients with 
chronic heart failure210. Furthermore, oral administration of glucocorticoids is a risk factor for 
heart disease211. In the aquaculture industry there is an increasing worry about stress-induced 
mortality20, 25. In particular, farmed fish experience social stress as well as stress related to 
handling etc. Cortisol is the major steroid stress hormone in salmonids as well as in humans, 
and cortisol receptors are expressed in the myocardium212 (and Paper IV). When applied to 
neonatal cardiomyocytes or fetal hearts, cortisol induce hypertrophy213-215. In Paper IV we 
showed that fish responding to stress with high plasma cortisol 1) have bigger hearts, 2) a 
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thicker compact myocardium, 3) increased expression of hypertrophic markers, 4) increased 
RCAN1 levels and 5) increased focal fibrosis and collagen expression. Based on these results, 
we suggest that cortisol-induced cardiac remodeling may be one of the underlying, 
explanatory factors for increased cardiac-related mortality in farmed salmonids. Interestingly, 
these results also suggest that NFAT activation in the diseased heart is an evolutionary 
conserved response.  
 
Future perspectives – calcineurin-NFAT signaling in heart failure 
As mentioned, the overall aim of this thesis is to expand the basic knowledge of molecular 
signaling pathways underlying development of heart failure, particularly the role of 
calcineurin-NFAT signaling. When so-called nodes that many signals converge on are 
identified, detailed, reductionist analyses contributing to the big puzzle are needed to 
understand the mechanisms, with the ultimate goal of developing novel therapeutic molecules. 
Based on current literature, calcineurin-NFAT is such a central node, and it is not unlikely 
that future therapeutics one day will target this pathway in the heart.     




The results presented in this thesis show that NFATc isoform-specific mechanisms exist 
within cardiomyocytes, such that ANGII activates NFATc1 and c4 while NE activates c1, c2 
and c3. In the myocardium of AS patients, all four NFATc isoforms are substantially up-
regulated, and despite a fraction being phosphorylated, NFATc activation was increased in 
these hearts at multiple levels. When pressure overload was relieved in mice, NFAT 
activation was reversed, suggesting that the detrimental effects of this pathway in the diseased 
heart may be targeted pharmacologically or surgically. Methodologically, measurements of 
NFATc isoform-specific activation and protein levels were made possible by evaluation of 
NFATc and phospho-NFATc antibodies using peptide arrays, blocking peptides and isoform-
specific overexpression.  
Using a syndecan-4 KO model, this thesis shows that syndecan-4 is essential for 
development of concentric myocardial hypertrophy following pressure overload in mice. In 
cardiomyocytes, mechanical stress-induced as well as autonomous growth-induced NFAT 
activation was mediated by syndecan-4, and calcineurin interacted directly with the 
cytoplasmic part of syndecan-4. When overexpressed, syndecan-4 activated NFAT by 
dephosphorylation. This effect was regulated by phosphorylation of the cytoplasmic domain 
of syndecan-4. Collectively, these results imply that syndecan-4 is a mechanosensor in the 
myocardium, regulating calcineurin-NFAT signaling in a pressure-overloaded heart.  
By investigating the myocardium of AS patients and rat models of chronic heart 
disease; hypertension, MI and AB, we show that the protein PTM called O-GlcNAc, which 
has been connected to NFAT signaling, is increased in all these chronically diseased hearts. A 
pharmacological increase in O-GlcNAc following MI suggested that O-GlcNAc promotes 
cardiac dysfunction after an infarction. Thus, our results suggest that O-GlcNAc is part of a 
chronic stress response in hypertrophic as well as in failing hearts.  
Finally, this thesis shows that in salmonid fish, the cortisol stress response is 
associated with cardiac hypertrophy, focal fibrosis and NFAT activation, suggesting NFAT 
activation to be a conserved mechanism in the diseased heart and stress to be an explanatory 
factor of stress-induced cardiac mortality in the fish farming industry.  
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Abstract
Sustained pressure overload leads to compensatory myocardial hypertrophy and subsequent heart failure, a leading cause
of morbidity and mortality. Further unraveling of the cellular processes involved is essential for development of new
treatment strategies. We have investigated the hypothesis that the transmembrane Z-disc proteoglycan syndecan-4, a co-
receptor for integrins, connecting extracellular matrix proteins to the cytoskeleton, is an important signal transducer in
cardiomyocytes during development of concentric myocardial hypertrophy following pressure overload. Echocardiographic,
histochemical and cardiomyocyte size measurements showed that syndecan-42/2 mice did not develop concentric
myocardial hypertrophy as found in wild-type mice, but rather left ventricular dilatation and dysfunction following pressure
overload. Protein and gene expression analyses revealed diminished activation of the central, pro-hypertrophic calcineurin-
nuclear factor of activated T-cell (NFAT) signaling pathway. Cardiomyocytes from syndecan-42/2-NFAT-luciferase reporter
mice subjected to cyclic mechanical stretch, a hypertrophic stimulus, showed minimal activation of NFAT (1.6-fold)
compared to 5.8-fold increase in NFAT-luciferase control cardiomyocytes. Accordingly, overexpression of syndecan-4 or
introducing a cell-permeable membrane-targeted syndecan-4 polypeptide (gain of function) activated NFATc4 in vitro. Pull-
down experiments demonstrated a direct intracellular syndecan-4-calcineurin interaction. This interaction and activation of
NFAT were increased by dephosphorylation of serine 179 (pS179) in syndecan-4. During pressure overload, phosphorylation
of syndecan-4 was decreased, and association between syndecan-4, calcineurin and its co-activator calmodulin increased.
Moreover, calcineurin dephosphorylated pS179, indicating that calcineurin regulates its own binding and activation. Finally,
patients with hypertrophic myocardium due to aortic stenosis had increased syndecan-4 levels with decreased pS179 which
was associated with increased NFAT activation. In conclusion, our data show that syndecan-4 is essential for compensatory
hypertrophy in the pressure overloaded heart. Specifically, syndecan-4 regulates stretch-induced activation of the
calcineurin-NFAT pathway in cardiomyocytes. Thus, our data suggest that manipulation of syndecan-4 may provide an
option for therapeutic modulation of calcineurin-NFAT signaling.
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Introduction
Sustained pressure overload leads to compensatory myocardial
hypertrophy and subsequent decompensation and heart failure, a
leading cause of morbidity and mortality. Mechanical stimuli,
circulating hormones, as well as autocrine and paracrine factors
are involved in initiating myocardial hypertrophy. Transduction
of mechanical stimuli may involve molecules that bind the
extracellular matrix to the cytoskeleton, but exactly which
molecules participate is still unknown. Further unraveling of
such signaling pathways is essential for defining novel therapeutic
targets.
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We have previously shown increased myocardial mRNA
expression of all four members of the syndecan family and increased
protein levels of syndecan-4 in the hypertrophic non-infarcted
region of the left ventricle following myocardial infarction [1].
Syndecan-4 is a transmembrane proteoglycan that connects
extracellular matrix proteins to the cardiomyocyte cytoskeleton
[2], and has been localized to costameres and Z-discs [3], potentially
important sites for signal transduction across the membrane [4,5].
Moreover, syndecan-4 is a co-receptor for several growth factors [6].
Various intracellular signaling pathways have been implicated in
transduction of mechanical stimuli during induction of cardiac
hypertrophy, including mitogen-activated protein kinase (MAPK)
cascades, protein kinase C (PKC)-mediated signaling [7–9] and the
calcineurin-nuclear factor of activated T-cell (NFAT) pathway [10].
Interestingly, syndecan-4 has been shown to bind and regulate
localization and activity of one of these, namely PKC-a [11].
We hypothesized that syndecan-4 acts as a signal transducer in
cardiomyocytes responding to an increase in mechanical stress on
the myocardium with subsequent activation of pro-hypertrophic
signaling. In this study, we show that syndecan-4 is essential for
development of concentric myocardial hypertrophy by acting as a
scaffolding protein for mechanical stretch-induced activation of
the calcineurin-NFAT pathway.
Results
Lack of syndecan-4 inhibits development of concentric
myocardial hypertrophy during pressure overload
Syndecan-42/2 mice had normal cardiac dimensions and
function compared to wild-type (WT) mice (Table S1). Three
weeks after inducing pressure overload by aortic banding (AB), WT
developed concentric left ventricular (LV) hypertrophy manifested
as a significant increase in posterior wall thickness (Fig. 1A–C). In
contrast, syndecan-42/2 mice displayed no increase in wall
thickness following AB (Fig. 1A–C), but a significant increase in
LV cross-sectional (Fig. 1D) and longitudinal diameter compared to
sham-operated syndecan-42/2 mice (syndecan-42/2-SHAB) and
WT-AB (Table S1). LV dilatation in syndecan-42/2-AB was
paralleled by reduced cardiac function compared to WT-AB, as
indicated by reduced LV fractional shortening (Fig. 1E). Accord-
ingly, syndecan-42/2-AB exhibited increased lung weight and left
atrial diameter, as well as increased levels of angiotensin II in serum
compared to WT-AB (Tables S1 and S2).
In agreement with the observed lack of concentric hypertrophy,
cardiomyocyte width was unchanged in syndecan-42/2-AB
compared to syndecan-42/2-SHAB (Fig. 1F), whereas in WT-
AB cardiomyocyte width was increased by 25% compared to WT-
SHAB. The cardiomyocytes were longer in both WT-AB (8%) and
syndecan-42/2-AB (10%) compared to respective controls.
LV histological sections demonstrated less densely packed
cardiomyocytes in syndecan-42/2 compared to WT after both
SHAB and AB (Fig. 1G). This finding was confirmed by
transmission electron microscopy, as syndecan-42/2 hearts
exhibited wider, irregular gaps between adjacent cardiomyocytes,
in addition to disorganized Z-lines, compared to WT following
both SHAB and AB (Fig. 1H). Myocardial wet weight was
significantly increased in syndecan-42/2 compared to WT only
following AB (Table S2). These data demonstrate increased
extracellular space in syndecan-42/2-AB compared to WT-AB, in
which concentric myocardial hypertrophy with wider cardiomy-
ocytes dominated. Immunohistochemical examination showed
equal staining for collagen type I (Fig. 1G), and immunoblotting
showed similar changes in collagen I, III and VIII following AB in
both genotypes (Table S2).
The lack of cardiomyocyte hypertrophy in syndecan-42/2 mice
was associated with lower expression of cardiac markers of
hypertrophy (Fig. 1I–J). Expression of a-skeletal actin, previously
shown to correlate with myocardial hypertrophy [12] was lower in
syndecan-42/2-AB than in WT-AB (Fig. 1I). Expression of B-type
natriuretic peptide (BNP), which has been shown to be regulated
by the transcription factor NFAT [13,14] and associated with
myocardial hypertrophy, was attenuated in syndecan-42/2-AB
compared to WT-AB (Fig. 1J). Expression of atrial natriuretic
peptide (ANP) was increased after AB, but there were no
differences between the two genotypes (Fig. 1K). Expression of
regulator of calcineurin 1–4 (RCAN1-4; also known as MCIP1), a
direct target for NFAT [14–16], was significantly lower in
syndecan-42/2-AB compared to WT-AB (Fig. 1L), indicating
reduced NFAT activity in syndecan-42/2 mice after AB. Both the
reduction in RCAN1-4 and in BNP are consistent with inhibition
of the calcineurin-NFAT pathway, as they have been shown to be
direct targets of NFAT in cardiomyocytes [14].
NFAT signaling is inhibited in syndecan-42/2 mice
To study the role of syndecan-4 in pro-hypertrophic NFAT
activation, NFAT phosphorylation (pNFAT) and NFAT luciferase
reporter activity were investigated in pressure overloaded hearts
and isolated cardiomyocytes subjected to mechanical stress and
autonomous hypertrophy. The calcineurin-dependent NFAT
isoform c4 (NFATc4) has previously been found to be sufficient
for cardiac hypertrophy [13] and to be activated in the
hypertrophic human myocardium [17], and thus activation of
this isoform was investigated in our study. Syndecan-42/2 mice
demonstrated reduced NFATc4 activation compared to WT
following AB, shown as increased pNFATc4 levels (Fig. 2A).
Increased levels of pNFAT indicate inhibition of the calcineurin-
NFAT pathway, since dephosphorylation of these transcription
factors by calcineurin is necessary for translocation to the nucleus.
Following sham-operation, there was a minimal reduction in
NFAT activation in syndecan-42/2 hearts.
To study whether syndecan-4 acts as a mechanotransducer for
activation of calcineurin-NFAT signaling in the pressure over-
loaded heart, cardiomyocytes were subjected to cyclic mechanical
stretch. In NFAT-luciferase reporter cardiomyocytes, 24 hrs of
mechanical stretch was sufficient to induce significant calcineurin-
dependent NFAT activation (Fig. S1A–B). Importantly, syndecan-
42/2-NFAT luciferase cardiomyocytes showed minimal activation
of NFAT (1.6-fold) compared to a 5.8-fold increase in NFAT-
luciferase control cells following mechanical stretch (Fig. 2B).
Accordingly, pNFATc4 levels were significantly higher in
syndecan-42/2 cardiomyocytes than in WT cells following
mechanical stretch (Fig. 2C). Finally, the role of syndecan-4 in
calcineurin-NFAT activation in cardiomyocytes subjected to
autonomous hypertrophy, was investigated. Syndecan-42/2
cardiomyocytes subjected to autonomous hypertrophy [18]
showed significantly higher levels of pNFATc4 compared to WT
cardiomyocytes (Fig. 2D), with a corresponding lower level of
NFAT activation as measured by luciferase activity in syndecan-
42/2-NFAT luciferase cells (Fig. 2E) and a reduced hypertrophic
response as measured by radioactive leucine-incorporation after
five days in culture (Fig. 2F). Altogether our data indicate that pro-
hypertrophic NFAT signalling was inhibited in cardiomyocytes
lacking syndecan-4.
Overexpression of membrane-localized syndecan-4 in
vitro activates NFAT
Increased levels of full-length syndecan-4 in the membrane of
HEK-293 cells caused diminished cytoplasmic pNFATc4 levels
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(Fig. 3A, upper panel) and reduced cytoplasmic/increased nuclear
NFAT levels (second panel from top), indicating that increased
syndecan-4 levels in the membrane induce NFAT activation by
dephosphorylation and translocation to the nucleus. To evaluate
syndecan-4 as a regulator of intracellular NFAT activation in
cardiomyocytes, we generated a cell-permeable peptide consisting
of the membrane and cytoplasmic regions of syndecan-4.
Cardiomyocytes treated with this peptide in vitro showed complete
dephosphorylation of NFATc4, while total amount was unaltered
(Fig. 3B), consistent with membrane-localized syndecan-4 being
important for NFAT activation through its intracellular domain in
cardiomyocytes. To evaluate if membrane localization of synde-
can-4 is important for NFAT activation, NFAT-luciferase
cardiomyocytes were treated with a cell-permeable peptide
consisting only of the cytoplasmic region of syndecan-4. This
peptide significantly reduced NFAT-luciferase activity (Fig. 3C),
indicating that NFAT activation is inhibited when syndecan-4 is
soluble, and not localized in the surface membrane.
We also investigated levels of enzymes that have been reported
to regulate NFAT phosphorylation in pressure overloaded hearts,
and hence may be involved in the syndecan-4-mediated NFAT
activation. There was, however, no difference in the level of
calcineurin in WT and syndecan-42/2 hearts after AB (Fig. S2 A).
Glycogen synthase kinase (GSK) 3-b phosphorylated by Akt is
known to antagonize calcineurin action and development of
cardiac hypertrophy by phosphorylating NFAT [19–21]. Both
GSK3-b and Akt were phosphorylated to the same extent in the
two genotypes following AB (Fig. S2 B–D). It has also been shown
that each of the three main branches of mitogen-activated kinases
(MAPK) directly modulates calcineurin-NFAT signaling and
hypertrophic response in the heart [22]. However, activation of
extracellular signal regulated protein kinase (ERK) 1/2, c-jun N-
terminal kinases (JNK) 2/3 and p38 was comparable in WT and
syndecan-42/2 hearts following AB (Fig. S2 E–J). Thus, lack of
syndecan-4 did not influence the calcineurin level, GSK-3b or
MAPK activation, suggesting that another mechanism regulating
NFAT phosphorylation was responsible for the activation of
NFAT by syndecan-4. As syndecan-4 is known to directly interact
with signaling molecules [23], we hypothesized that syndecan-4
interacts directly with calcineurin.
Figure 2. Decreased activation of the calcineurin-nuclear factor of activated T-cell (NFAT) pathway in syndecan-42/2 mice in
response to aortic banding. (A) Phosphorylated NFATc4 (pNFATc4) and NFATc4 levels in the left ventricle of wild-type (WT) and syndecan-42/2
(Syn-42/2) mice 24 h after aortic banding (AB) or sham-operation (SHAB) analyzed by immunoblotting. An NFAT-rich cell lysate (Ramos) was used as
control for NFAT-positive protein bands (n = 5–15). (B) Luciferase (luc) activity in neonatal cardiomyocytes from NFAT-luciferase and Syn-42/2-NFAT-
luciferase mice subjected to 24 h of cyclic mechanical stress (MS) (n = 12–33). (C) pNFATc4 levels in WT and Syn-42/2 neonatal cardiomyocytes
subjected to 24 h of cyclic MS (n = 9–12). (D) pNFATc4 and NFATc4 levels in neonatal cardiomyocytes from Syn-42/2 and WT mice subjected to
autonomous hypertrophy (n = 4). (E) Luciferase activity in neonatal cardiomyocytes from NFAT-luciferase and Syn-42/2-NFAT-luciferase mice
subjected to autonomous hypertrophy (n = 9–18). (F) Radioactive leucine incorporation in Syn-42/2 and WT mice subjected to five days of
autonomous hypertrophy (n = 6–24). GAPDH and actin were used for loading control. Values are mean 6 s.e.m.
doi:10.1371/journal.pone.0028302.g002
Figure 1. Lack of syndecan-4 inhibits development of concentric hypertrophy three weeks after induction of pressure overload. (A)
Representative cross-sections (HE staining) of the hearts of wild-type (WT) and syndecan-42/2 (Syn-42/2) mice after sham operation (SHAB) or aorta
banding (AB) (n = 3). Scale bars, 0.1 mm. (B) Representative 2D and M-mode tracings from the left ventricle (LV) (LVDd, LV diameter in diastole) (n = 9–
10). Echocardiographic measurements of (C) posterior wall thickness in diastole (PWd) and (D) LVDd normalized to tibia length (TL), and (E) LV
fractional shortening (LVFS) (n = 9–10). (F) Cardiomyocyte width (3 animals in each group). (G) Representative sections of LV myocardium stained for
collagen I (brown staining indicates collagen I) (n = 2–3). Scale bars, 100 mm. (H) Representative transmission electron microscopy images of LV
myocardium (n= 2). Scale bars, 5 mm. Arrows indicate intercellular spaces and arrowheads indicate Z-lines. Real-time PCR analysis of (I) a-skeletal actin
(a-ska), (J) B-type natriuretic peptide (BNP), (K) atrial natriuretic peptide (ANP) and (L) regulator of calcineurin 1–4 (RCAN1-4). mRNA levels were
normalized to GAPDH in LV (n = 10). Values are mean 6 s.e.m.
doi:10.1371/journal.pone.0028302.g001
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Calcineurin associates with syndecan-4, and the
association is regulated by dephosphorylation of serine
179 in syndecan-4 during pressure overload
To examine whether calcineurin associates with syndecan-4, pull-
down experiments using biotinylated peptides spanning the
cytoplasmic part of syndecan-4 were performed. Recombinant
His-trigger factor (TF)-calcineurin subunit A (CnA) was pulled down
with syndecan-4 and to a lesser extent with syndecan-2 (Fig. 4A,
alignment of syndecan-2 and 4 shown in Fig. 4B). Then, syndecan-4
and CnA were co-transfected into HEK-293 cells and immunopre-
cipitated with syndecan-4 (Fig. 4C; epitope mapping of syndecan-4
antibodies shown in Fig. S3) and CnA (Fig. 4D) antibodies.
Figure 3. Membrane-localized syndecan-4 activates nuclear factor of activated T-cell (NFAT) in vitro. Phosphorylated NFATc4 (pNFATc4),
NFATc4 and syndecan-4 levels in (A) HEK-293 cells overexpressing full-length HA-tagged syndecan-4 (HA-syn-4, Cyt = cytoplasmic, Nuc =nuclear,
Mem=membrane, EGFR= epidermal growth factor receptor (marker of membrane fraction)) (n = 12). Wild-type (WT) cardiomyocytes treated with a
cell-permeable peptide consisting of the membrane and cytoplasmic parts of syndecan-4 (syn-4 (mem+cyt)-HA) (n = 4), analyzed by immunoblotting
(B), and NFAT-luciferase reporter cardiomyocytes treated with a cell-permeable peptide consisting of the cytoplasmic part of syndecan-4 only,
analyzed by luciferase activity (n = 3) (C). GAPDH, histone H4, EGFR and actin were used as loading controls. Values are mean 6 s.e.m.
doi:10.1371/journal.pone.0028302.g003
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Immunoblotting revealed the presence of co-immunoprecipitated
CnA (Fig. 4C, upper panel) and syndecan-4 (Fig. 4D, upper panel).
Phosphorylation of serine 179 (pS179) in the intracellular domain
of syndecan-4 has been shown to regulate protein interactions, such
as PKCa association [24]. Pull-down experiments using biotinylated
peptides spanning either the non-phosphorylated or phosphorylated
cytoplasmic part of syndecan-4 showed that less recombinant His-
TF-CnA bound to pS179-syndecan-4 than to non-phosphorylated
Figure 4. Association of syndecan-4 with calcineurin A (CnA). (A) Pull-down experiments with biotinylated peptides covering cytoplasmic
domains of syndecan-1–4 were performed using recombinant His-trigger factor (TF)-CnA, and precipitates immunoblotted for presence of His-TF-CnA
(n = 3). (B) Alignment of syndecan-4 and syndecan-2. Black boxes indicate similar amino acids within consensus region. Lysates from HEK-293 cells co-
transfected with syndecan-4 and CnA subjected to immunoprecipitation with (C) anti-syndecan-4 (n = 3) or (D) anti-CnA (n = 3) were immunoblotted
with anti-CnA or anti-syndecan-4, respectively. Pull-down experiments with biotinylated peptides covering non-phosphorylated or phosphorylated
cytoplasmic part of syndecan-4 were performed using recombinant His-TF-CnA (E) or left ventricular (LV) tissue before immunoblotted for presence
of endogenous CnA (n = 3) and PKC-a (n = 2) (F). (G) LV tissue extracts from WT-SHAB and WT-AB were immunoprecipitated with anti-syndecan-4 or
control IgG and lysates and immunoprecipitates immunoblotted for presence of PKC-a, CnA and calmodulin (CaM, n = 2). (H) Relative pS179-
syndecan-4/total syndecan-4 levels in aorta-banded (AB) versus sham-operated (SHAB) WT LV tissue (n = 3). Calsequestrin was used for loading
control. Values are mean 6 s.e.m.
doi:10.1371/journal.pone.0028302.g004
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syndecan-4 (Fig. 4E). Furthermore, endogenous CnA in LV tissue
was pulled down with the non-phosphorylated form, but only
minimally with pS179-syndecan-4 (Fig. 4F). As expected, less PKCa
bound to pS179-syndecan-4.
In immunoprecipitation experiments using LV tissue, more co-
precipitation of CnA with syndecan-4 was observed after AB
compared to sham (Fig. 4G). Furthermore, co-immunoprecipita-
tion of the CnA co-activator calmodulin and PKCa were also
increased after AB (Fig. 4G). Since pS179 appeared to inhibit
syndecan-4-CnA association, pS179-syndecan-4 levels were ana-
lyzed following AB using a specific pS179-syndecan-4 antibody.
pS179-syndecan-4 levels were found to be reduced by 40% in
WT-AB versus WT-SHAB, favoring CnA-syndecan-4 association
following AB (Fig. 4H). In the murine heart, syndecan-4 was
identified as separate bands at ,20–24 kDa consistent with
reported sizes of syndecan-4 protein [25].
Consistent with phosphorylation of syndecan-4 being a
regulator of CnA association, expression of S179E-syndecan-4
(mimicking constitutive S179 phosphorylation) increased pNFAT
levels compared to WT syndecan-4 and was similar to non-
transfected cells (Fig. 5A). Conversely, expression of S179A-
syndecan-4 (mimicking no S179 phosphorylation) reduced
pNFATc4 levels compared to non-transfected cells and WT
syndecan-4 expression (Fig. 5A), indicating that membrane-bound
syndecan-4 is an activator of CnA.
Finally, co-transfection of syndecan-4 and CnA into HEK-293
cells resulted in reduced pS179 levels compared to syndecan-4
transfection alone, indicating that calcineurin regulates its own
binding and activation by dephosphorylation of syndecan-4
(Fig. 5B).
Intracellular V- and C2-regions in syndecan-4 bind to the
autoinhibitory domain of calcineurin
The cytoplasmic region of syndecan-4 consists of three regions;
two that are conserved between the syndecans, C1 and C2, and
the isoform-specific V-region (Fig. 6A). Alignment of syndecan-4
with other CnA-binding proteins; NFAT [26], AKAP79 [27] and
calcineurin inhibitor (cain) [28], revealed a putative CnA-binding
motif (PIxIxIT) in the V-region (Fig. 6B). The cytoplasmic region
of syndecan-4 was synthesized as overlapping 20-mer peptides on
a membrane overlayed with active CnA or endogenous calci-
neurin in tissue lysate followed by immunoblotting. Strongest
CnA-binding was observed in the amino acid sequence
SYDLGKKPIYKKAPTNEFYA, which contains the PIxIxIT–
similar motif and the C2-region (Fig. 6C, amino acids 179–198,
underlined).
To identify the syndecan-4 binding region, full-length CnA
protein was synthesized as 20-mer peptides and overlayed with a
biotin-syndecan-4 (171–198) peptide followed by anti-biotin-
peroxidase conjugated immunoblotting. Syndecan-4 binding was
located to the autoinhibitory domain in CnA (Fig. 6D, middle
panel and Fig. 6E). Consistent with our other data, a biotin-
phospho-peptide (pS179-syndecan-4) bound only minimally to
CnA (Fig. 6D, right panel).
Figure 5. Level of phosphorylated syndecan-4 regulates NFAT activation and is decreased by calcineurin. (A) Phosphorylated NFATc4
(pNFATc4), NFATc4 and syndecan-4 levels in HEK-293 cells transfected with HA-syn-4, HA-syn-4-S179A (mimicking no S179 phosphorylation) or HA-
syn-4-S179E (mimicking constitutive S179 phosphorylation) (n = 6–9) and (B) pS179-syndecan-4, syndecan-4 and calcineurin A (CnA) levels in HEK-293
cells co-transfected with CnA and HA-syn-4 or HA-syn-4 alone (n = 6) analyzed by immunoblotting. Actin was used a loading control. Values are mean
6 s.e.m.
doi:10.1371/journal.pone.0028302.g005
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Increased myocardial syndecan-4 levels and reduced
serine 179 phosphorylation in patients with aortic
stenosis
In order to demonstrate a direct relevance to human heart
disease, we examined levels of syndecan-4 and syndecan-4
phosphorylation in biopsies taken peroperatively from patients
with hypertrophic myocardium due to aortic stenosis and controls.
We found a 92 and 72% increase in syndecan-4 mRNA and
protein levels, respectively, in patients with aortic stenosis, with a
corresponding 21% reduction in pS179-syndecan-4/total synde-
can-4 ratio and a 197% increase in RCAN1-4 mRNA (Fig. 7 A–
C), indicating a state that favors calcineurin-NFAT activation in
the hypertrophic human heart.
Discussion
Our main findings are that syndecan-42/2 mice did not develop
concentric hypertrophy in response to chronic pressure overload,
and that lack of syndecan-4 specifically inhibited the calcineurin-
NFAT pathway in vivo and in vitro. In particular, NFAT activation
was almost totally inhibited following stretch of syndecan-42/2
cardiomyocytes, whereas it was substantially increased in wild-type
cardiomyocytes in response to stretch. Syndecan-4 was shown to
bind to the autoinhibitory domain in calcineurin, and this binding
was enhanced by dephosphorylation of S179 in syndecan-4
(depicted in Fig. 8). Finally, dephosphorylation of syndecan-4
occurred during pressure overload both in mice and man.
Activation of the calcium- and calmodulin-dependent phospha-
tase calcineurin is necessary and sufficient to induce pathological
cardiac hypertrophy [13,29–32]. Calcineurin dephosphorylates
the transcription factors belonging to the NFAT family, leading to
their activation [13]. Most studies inhibiting calcineurin activity
have produced a significant attenuation of pathological hypertro-
phy [32], which is in accordance with our in vivo findings including
lack of concentric hypertrophy during pressure overload in
syndecan-42/2 mice.
Figure 6. V- and C2-region in syndecan-4 bind to the autoinhibitory domain in calcineurin A (CnA). (A) Schematic illustration of the
three cytoplasmic regions in syndecan-4. (B) Alignment of syndecan-4 with other calcineurin binding motifs. Identification of PIxIxIT-similar motif
(6represents any amino acid) in V-region. Black boxes indicate similar amino acids within the consensus region. (C) Syndecan-4 residues important for
CnA binding were identified by overlaying an array of immobilized syndecan-4 20-mer peptides with 4 amino acids offset with recombinant CnA (left
panel). (D) CnA residues important for syndecan-4 binding were identified by overlaying an array of immobilized CnA peptides with 3 amino acids
offset with a biotinylated peptide covering the cytoplasmic region of syndecan-4 (middle panel) or the phosphoform (pS179, right panel).
Immunoblots without pre-incubation with CnA (C, right panel) or biotinylated peptide (D, left panel) were used as negative controls. Underlined
amino acids indicate those relevant for CnA-syndecan-4 binding. Overlay experiments were performed three times with similar results. (E) Schematic
illustration of various interaction domains in CnA. Autoinhibitory domain is defined to amino acids 467–491 [53].
doi:10.1371/journal.pone.0028302.g006
Figure 7. Increased myocardial syndecan-4 levels and reduced serine 179 phosphorylation (pS179) in patients with aortic stenosis.
(A) Real-time PCR analysis of syndecan-4 (n = 9), (B) immunoblots of pS179-syndecan-4 (top panel) and syndecan-4 (bottom panel) levels with relative
syndecan-4 and pS179-syndecan-4/syndecan-4 ratios (n = 3) and real-time PCR analysis of regulator of calcineurin 1–4 (RCAN1-4) (n = 7) (C) in
myocardial biopsies from patients with severe aortic stenosis (AS) versus control patients. GAPDH was used for loading control. Values are mean 6
s.e.m.
doi:10.1371/journal.pone.0028302.g007
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Signaling molecules involved in the myocardial hypertrophic
response to increased mechanical stress, and regulators of the
calcineurin-NFAT pathway are only partially known. It has been
suggested that mechanical signals in cardiomyocytes converge on
membrane proteins such as integrins [33,34]. In addition, studies
indicate a role for mechanotransducer complexes involving the Z-
discs and related proteins [35,36]. As syndecan-4 connects the
extracellular matrix proteins to the cytoskeleton, is a co-receptor
with a5b1 integrin [37] and is localized to costameres and Z-discs
[3], we hypothesized that syndecan-4 senses mechanical stress and
activates pro-hypertrophic signaling responses such as the
calcineurin-NFAT pathway. A role for syndecan-4 as a mechan-
otransducer has previously been suggested by us [1] and others
[38]. We demonstrate that following stretch, NFAT activation was
nearly abolished in cardiomyocytes lacking syndecan-4. We also
show that lack of syndecan-4 reduced NFAT activation and
expression of the NFAT target gene RCAN1-4 during increased
mechanical stress induced by left ventricular pressure overload.
These data clearly indicate that syndecan-4 is a regulator of NFAT
activity in cardiomyocytes in response to increased mechanical
stress.
We then studied the mechanism for activation of calcineurin-
NFAT signaling by syndecan-4, and showed that CnA binds
directly to the intracellular V- and C2-regions in syndecan-4. The
V-region confers binding specificity for each syndecan family
member and the syndecan-4 V-region contains a PIxIxIT-similar
motif. A loosely conserved PIxIxIT motif has been suggested to
represent the CnA binding site in AKAP79 [27], NFATs [26], cain
[28,39] and RCAN1-4 [16,40]. The syndecan-4 binding region
was located to the autoinhibitory domain of CnA. This domain is
thought to block the active site within the catalytic region of CnA,
rendering the phosphatase inactive [41–43]. Increased syndecan-
4-calmodulin co-precipitation was observed during pressure
overload. Calmodulin has been found to increase calcineurin
activity more than 20-fold. Interestingly, the PDZ domain of
CASK, which is known to bind calmodulin, is also able to bind to
the C2 region of syndecans [44]. Thus, a direct interaction
between CnA and syndecan-4 might facilitate activation of
calcineurin by bringing calmodulin and CnA in close proximity.
We also demonstrated that CnA-syndecan-4 interaction is
regulated by phosphorylation of S179 in syndecan-4. During
cardiac pressure overload, we found a decrease in phosphorylated
S179-syndecan-4 and an increased association between syndecan-
4 and calcineurin, suggesting that dephosphorylation of pS179-
syndecan-4 causes increased binding of calcineurin. More directly,
we showed that expression of a construct mimicking absent S179
phosphorylation (S179A) increased NFAT activity. These results
indicate that alterations in syndecan-4 phosphorylation level may
have functional significance for development of cardiac hypertro-
phy. Moreover, the significantly reduced myocardial phosphory-
lation of S179-syndecan-4/total syndecan-4 ratios combined with
increased NFAT activation found in patients with aortic stenosis
indicates a direct relevance for this mechanism in human heart
disease. Interestingly, a reduction in phosphorylation of S179 in
syndecan-4 was induced by overexpression of CnA, suggesting that
calcineurin dephosphorylates syndecan-4 in vivo and thereby
regulates its own activity.
Concentric hypertrophy of the myocardium during pressure
overload is considered to be a compensatory response of the heart
to deal with increased afterload during such conditions as aortic
stenosis and hypertension. Lack of compensatory hypertrophy
may thus cause myocardial dilatation and possibly dysfunction.
Accordingly, Meguro et al. [45] showed that inhibition of
calcineurin-NFAT activation with cyclosporine attenuated pres-
sure overload hypertrophy and enhanced the susceptibility to heart
failure. Similarly, we found reduced cardiac function and
attenuated concentric hypertrophy in syndecan-42/2-AB. Al-
though our data clearly indicate syndecan-4-mediated, pro-
Figure 8. Schematic illustration of proposed syndecan-4-CnA interaction. Phosphorylation of S179 in syndecan-4 renders the CnA-NFAT
pathway inactive (left box). Dephosphorylation of syndecan-4 induces binding of CnA and calmodulin (CaM) to syndecan-4 and subsequent
activation of the NFAT transcription factor (right box).
doi:10.1371/journal.pone.0028302.g008
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hypertrophic NFAT activation in cardiomyocytes, syndecan-4
may also mediate other effects in the pressure-overloaded heart. In
a recent study, syndecan-42/2 mice were shown to have impaired
cardiac function and increased mortality following myocardial
infarction [46], while in another study, cardiac function was
improved and NFAT activation increased in syndecan-42/2 mice
after infarction [47], suggesting additional layers of complexity in
syndecan-4-dependent NFAT regulation and remodeling of the
heart.
In summary, our data show that syndecan-4 is essential for
development of compensatory myocardial hypertrophy in the
pressure overloaded myocardium. Specifically, syndecan-4 reg-
ulates stretch-induced activation of the pro-hypertrophic calci-
neurin-NFAT signaling pathway in cardiomyocytes. Syndecan-4
was found to bind to the autoinhibitory domain of calcineurin
and this binding was regulated by phosphorylation of syndecan-
4. Patients with aortic stenosis exhibited decreased pS179-
syndecan-4/syndecan-4 ratios, indicating a direct relevance to
human myocardial hypertrophy. In conclusion, our data indicate
that syndecan-4 is a scaffolding protein for activation of
calcineurin-NFAT signaling and development of concentric
myocardial hypertrophy during pressure overload, both in mice
and man.
Methods
The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NIH publication No. 85-23, revised 1996) and was
approved by the Norwegian National Animal Research Commit-
tee (permit of approval number STFDU1736). The human
myocardial biopsy protocol was approved by the Regional
Committee for Research.
Ethics in Eastern Norway (permit of approval number
1.2005.316) and conforms to the Declaration of Helsinki.
Animal model and transthoracic echocardiography
Banding of the ascending aorta was carried out in 7 week old
WT (C57BL/6, Møllergaard, Denmark) and syndecan-42/2 mice
[48]. Anaesthesia was induced with .5% isoflurane gas and
,95% O2 in a gas chamber, followed by tracheostomy and
ventilation with 2% isoflurane and 98% O2, with a tidal volume of
350 ml and a respiratory frequency of 160 min21 on a MiniVent
ventilator (Harvard Apparatus, Holliston, MA 01746, USA). A
sternal split of the cranial 1/3 of the sternum was performed and
an 8-0 silk ligature was tied around the ascending aorta and a 26G
blunted needle, which was subsequently removed. Sham-operated
animals underwent the same procedure without banding of the
aorta. After twenty-one days echocardiography was carried out
using a VEVO 2100 (Visualsonics, Toronto, Canada) before the
animals were sacrificed. Echocardiographic examinations were
performed under standardized conditions with the animals in the
supine position, spontaneously breathing 1.5% isoflurane and
98.5% O2 on a mask. Echocardiographic data were analyzed off-
line using VEVO 2100 1.1.0 software from Visualsonics. Three
representative cycles were analyzed and averaged. Two-dimen-
sional (2D) images of the LV were obtained both in long and short
axes. Short axis recordings were obtained at the level of the
papillary muscle. M-mode tracings were recorded at the level of
both the papillary muscles and the aortic valves, with 2D
guidance. LV wall thickness and cavity dimensions were measured
through the largest diameter of the ventricle both in systole and
diastole. LV fractional shortening (LVFS) in percent, was
calculated using the following formula.
LVFS~ LVDd{LVDsð Þ=LVDd|100
where LVDd is LV diameter in diastole, and LVDs is LV diameter
in systole. Doppler recordings were obtained in the left parasternal
long axis position. Pulsed wave Doppler was used for measuring
flow velocities across the constriction, as well as in the left
ventricular outflow tract (LVOT) and in the mitral annulus.
Cardiac output (CO) was calculated in LVOT using the following
equation
CO~LVOT VTI|p| diameter=2ð Þ2|HR
where VTI is the velocity time integral, HR is heart rate and
diameter is measured in LVOT.
The LV, right ventricular free wall and lungs were weighed and
normalized to tibia length. Only mice with a maximum flow
velocity across the stricture .3 m/s and ,4 m/s 24 hours after
AB and .4 m/s and ,6 m/s three weeks after AB were included
(mean values, 4.360.1 m/s in syndecan-42/2 mice versus
4.360.1 m/s in WT).
LV pressure measurements
Immediately after finishing echocardiography, a 1.4-Fr microtip
pressure transducer catheter (SPR-671, Millar Instruments,
Houston, TX) was introduced into the left ventricle through the
right carotid artery for measurements of LV pressures and
calculations of its maximal positive and negative first derivatives.
Data recorded from 10–15 consecutive beats were analyzed. LV
pressure measurements were performed in un-operated WT and
syndecan-42/2 mice, and not following AB as the aortic
constriction was too tight to allow for retrograde insertion of the
catheter.
Estimation of LV fluid content
Three weeks after AB or SHAB LV from WT and syndecan-
42/2 mice were weighed immediately upon dissection, cut into
pieces and dried for 24 h at 90uC, before weighing again.
Angiotensin II concentration in plasma
Plasma was extracted from full-blood containing 0.44 mM o-
phenanthroline, 25 mM EDTA, 1 mM p-hydroxy-mercuriben-
zoic acid and 0.12 mM pepstatin A and the concentration of
angiotensin II was measured using the Max Human Angiotensin 2
ELISA Kit according to the manufacturers protocol (EA3501-1,
Assaypro, St. Charles, MO) in WT and syndecan-42/2 mice three
weeks after AB or SHAB.
Human myocardial biopsies
LV apical myocardial biopsies (10 mg) were obtained immedi-
ately before crossclamping the aorta in twelve patients with severe
aortic stenosis and twelve control patients with coronary artery
disease during elective aortic valve replacement and coronary
artery bypass operations, respectively. Biopsies were taken from a
normal appearing and contracting area using a 22G needle (Easy
Core Biopsy System, Boston Scientific International S.A., Cedex,
France). Patients 40–85 years old with symptomatic aortic stenosis,
a mean aortic gradient .50 mmHg or an aortic valve area
,0.7 cm2, and without significant coronary artery disease were
included in the aortic stenosis group. Patients 40–85 years old with
stable angina pectoris, no known previous myocardial infarction,
ejection fraction .50%, and without significant valve disease were
included in the control group. The patients had no chest pain or
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electrocardiographic signs suggesting ongoing ischemia preopera-
tively. Informed written consent was obtained from each patient.
NFAT-luciferase mice
The NFAT-luciferase mice have nine copies of an NFAT-binding
site from the interleukin (IL)-4 promoter (59-TGGAAAATT-39)
inserted upstream of the luciferase reporter gene, driven by the a-
myosin heavy chain promoter [31], and were a kind gift from Jeffery
D. Molkentin (Cincinnati Children’s Hospital Medical Center,
University of Cincinnati, Cincinnati, OH). Neonatal mice from the
progeny were used for isolation of cardiomyocytes.
Syndecan-42/2-NFAT luciferase mice
Syndecan-42/2-NFAT luciferase reporter mice were generated
by crossing syndecan-42/2 mice with the NFAT-luciferase mice.
Neonatal mice from the progeny were used for isolation of
cardiomyocytes.
Quantification of luciferase activity
For measurements of luciferase activity, cardiomyocytes were
harvested according to the Luciferase Assay System protocol
(E1500, Promega) and luminescence from sample duplicates was
quantified on a Victor 3 1420 Multilabel Counter (PerkinElmer,
Waltham, MA).
Adult cardiomyocyte isolation and cell size
measurements
Cardiomyocytes were enzymatically isolated from WT and
syndecan-42/2 mice three weeks after AB or SHAB (n= 3 in each
group) by cannulating the aorta and retrogradely perfusing with a
Ca2+-free Tyrode’s solution containing 0.05 mg/ml collagenase
(Yakult, Tokyo, Japan) for 10 min. The left ventricle was then
removed and minced, cardiomyocytes precipitated, and extracel-
lular [Ca2+] was gradually increased. Cells were stored at room
temperature until use. Cell length and width measurements were
determined in a genotype-blinded manner from 2-dimensional
images of randomly selected cells.
Electron microscopy
Two hearts from WT and syndecan-42/2 mice, respectively,
obtained three weeks after AB or SHAB were perfused with 2.0%
glutaraldehyde buffered in 0.2 M cacodylate at pH 7.4 for
15 min. LV blocks (about 1 mm3) were fixed in 2% glutaralde-
hyde in cacodylate buffer for 2 h, rinsed overnight and transferred
to a 1% OsO4 solution for 30 min on ice. After rinsing in
cacodylate, the specimens were dehydrated in graded ethanols and
embedded in Epon. Ultrathin sections (60–100 nm) were stained
with uranyl acetate and lead citrate and examined and
photographed in a Tecnai G2 spirit BioTWIN 120 kV, LaB6,
Transmission Electron Microscope with 4 k Eagle camera (FEI
Company, Eindhoven, The Netherlands). All images were
examined by two investigators, blinded for mouse identity.
Histology
Hearts fixed in formalin were processed into paraffin wax. Six 4
mm thick slices were cut along the short axis from the mid-
ventricular level of each tissue sample. Slices were stained with
hematoxylin-eosin for morphology.
Immunohistochemistry
The excised hearts were placed in ice-cold phosphate-buffered
saline (PBS, pH 7.4), quickly embedded in Tissue-TekTM O.C.T.
compound (Sakura Finetek, Torrance, CA, USA) and frozen in
dry ice-cooled isopropanol before storing at 270uC. Five mm thick
sections were cut using the Cryostat 1720 from Leitz, Wetzlar,
Germany and collected on SuperFrostHPlus slides (Menzel-Gla¨ser,
Braunschweig, Germany). Sections were fixed for 5 minutes in
acetone at 220uC and air dried. After rinsing in Tris-buffered
saline (TBS, pH 7.6) containing 0.05% Tween 20, sections were
incubated with the DAKO Peroxidase Blocking Reagent (DAKO,
Glostrup, Denmark) for 15 minutes at 37uC followed by TBS
rinsing. Sections were then incubated for 30 minutes at 37uC with
affinity-purified antibodies (rabbit) against collagen type I (1:100
dilution) (Rockland, Gilbertsville, PA). After three washes in TBS
the primary antibody was labelled for 30 minutes using the
DAKO EnVisionTM +, Peroxidase, Rabbit K 4010 system and
3,39-diamino-benzidine tetrahydrochloride as the chromogen.
Sections were counterstained with hematoxylin for 1–2 minutes,
mounted and examined under a Leitz Aristoplan microscope.
RNA isolation and real time quantitative PCR
Total RNA was isolated from the LV of mice and LV biopsies
from patients using RNeasy mini kit (Cat# 74106, Qiagen Nordic,
Norway). RNA quality was determined using 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA). RNA integrity number
(RIN) .7.5 was required for further analysis. Reverse transcrip-
tion reactions were performed with iScript cDNA Synthesis Kit
(Bio-Rad Laboratories, Inc., Hercules, CA). Pre-designed Taq-
Man assays (Applied Biosystems, Foster City, CA) were used to
determine gene expression of a-skeletal actin (Mm00808218_g1),
ANP (Mm01255748_g1), BNP (Mm00435304_g1), RCAN1-4
(Mm01213406_m1) and GAPDH (Mm03302249_g1) in WT
and syndecan-42/2 mice three weeks after AB or SHAB, and
expression of syndecan-4 and RCAN1-4 (Hs01120954_m1) in
human myocardial biopsies (Hs01120909_m1). The results were
detected on an ABI PRISM 7900 Sequence Detection System
(Applied Biosystems).
Tissue extracts
LV tissue extract A. Frozen murine LV tissue was pulverized
in a mortar with liquid nitrogen before transfer to lysis buffer
(20 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5%
Triton) with protease (1 mM PMSF and Complete EDTA-free
tablets; Roche Diagnostics) and phosphatase inhibitors (1 mM
Na3VO4, 10 mM NaPP and 50 mM NaF) in a glass tube. The
samples were homogenized with a Polytron 1200 and centrifuged
at 70 0006g for 60 min at 4uC. Supernatants were collected and
stored at 270uC. LV tissue extract B. Frozen murine LV tissue
or human myocardial LV biopsies were homogenized using a
Polytron 1200 in a PBS buffer containing 1% Triton X-100, 0.1%
Tween20 and protease (Complete EDTA-free tablets) and
phosphatase inhibitors (10 mM NaF and 1 mM Na3VO4),
incubated on ice for 30 min and centrifuged at 14 000–20 000 g
for 10 min. The resulting supernatants collected and stored at
270uC. Protein concentrations were determined by Micro BCA
Protein Assay Kit (Pierce, Rockford, IL).
Immunoprecipitation
LV extracts (500 mg tissue extract A) from WT mice 24 h after
SHAB or AB were incubated with antibodies (2 mg) and 30 ml
protein A/G agarose beads (Santa Cruz Biotechnology, Santa
Cruz, CA, sc-2003) overnight at 4uC. Immunocomplexes were
washed once for 10 min in immunoprecipitation (IP)-buffer
(20 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1%
Triton), four times 10 min in IP-buffer with high salt (1 M) and
finally once for 10 min in IP-buffer, boiled in SDS loading buffer
and analyzed by immunoblotting. Rabbit IgG (sc-2027) and goat
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IgG (sc-2028) were used as negative controls. Immunocomplexes
from HEK-293 extracts (in presence of 1.5 mM CaCl2) were
washed three times in lysis buffer (20 mM Hepes, pH 7.5,
150 mM NaCl, 1 mM EDTA, 0.5% Triton). Immunoprecipitates
were analyzed by immunoblotting.
Isolation of neonatal mouse cardiomyocytes
Solutions used; Trypsin solution: 1.11 mg Trypsin powder
(Sigma, St.Louis, MO) mixed with 30 ml cold Hanks Balanced
Salt Solution (HBSS, Gibco-BRL, Gaithersburg, MD). Collagenase
solution: 23.25 mg collagenase Type-2 powder (Worthington
Biochemical, Lakewood, NJ) mixed with 100 ml HBSS. Light-
medium: 375 ml DMEM (Gibco-BRL), 125 ml M-199 (Gibco-
BRL), 5 ml 1006 penicillin/streptomycin/glutamine solution
(Sigma) and 5 ml 1 M HEPES (Gibco-BRL). Dark medium: Light
medium mixed with 25 ml horse serum (Gibco-BRL) and 12.5 ml
fetal bovine serum (Gibco-BRL). All solutions were filter sterilized.
The procedure is based on a protocol by Masahiko Hoshijima,
University of California, San Diego, CA. In brief, 40–60 neonatal
pups were quickly decapitated and their hearts removed and
placed in cold HBSS. The LV cut into pieces were digested for
166 min and 7610 min in 18 ml of collagenase solution. Each
resulting supernatant was transferred to a 50 ml conical tube with
cold dark medium on ice, containing serum to inactivate the
collagenase. The pooled supernatants were centrifuged at 1246 g
for 6 min and the pellet resuspended in warm dark medium. The
cells were plated in 150 cm2 flasks and incubated at 37uC for
2675 min for differential plating. The resulting suspension with
unattached cardiomyocytes was spun at 1246g for 10 min to
pellet cells. After resuspension of pellet in warm dark medium, the
cells were counted and plated in 6-well dishes or Omni Trays
(Omni Tray Cell Culture Treated w/Lid, Nalge Nunc Interna-
tional, Rochester, NY) coated with 0.2% gelatin (Sigma) added
0.1% fibronectin (Sigma) at a density of 2.56105 cells/ml, and
incubated at 37uC.
Treating cardiomyocytes with peptides
Isolated neonatal cardiomyocytes were cultured for two days in
6-well plates at a density of 0.66106 cells/ml. Cardiomyocytes
were treated with the arginine-coupled (50 mM) peptide (Genscript
Corp.) for 90 min and washed twice with RNase-free PBS before
being harvested in IP-buffer (20 mM Hepes, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100) with protease inhibitors
(Complete Mini EDTA-free tablets, Roche) or for quantification of
luciferase activity as described above. Harvested protein was
analyzed by immunoblotting. Peptide-treatment for longer time-
periods have been shown to result in considerable degradation of
the peptides [49].
Cyclic mechanical stretch of neonatal cardiomyocytes
Isolated neonatal cardiomyocytes were plated on collagen I
coated silicone membranes at a density of 2.56105 cells/ml. Cyclic
mechanical stretch was induced by stretching cells for 10 min–
24 hours (10%, 1 Hz) using the FlexCell Tension System FX-4000
(Dunn Labortechnik, Germany). Cyclosporin A (CsA) (SandIm-
mun Neoral, 500 ng/ml; 586107, Novartis, Switzerland) was used
as a calcineurin inhibitor with vehicle serving as control
(Cremophore, C5135, Sigma).
Quantification of 3H-leucine incorporation
Isolated cardiomyocytes were left in culture for two-five days in
order to induce autonomous hypertrophy [18]. Five mCi/ml 3H-
leucine (American Radiolabel Chemicals, MO) was added to the
medium at day two in culture. The cells were washed 6 times in
95% EtOH before harvested in 0.2 mol/l NaOH at day five in
culture. Serum-stimulated cells served as positive control. 3H-
leucine incorporation was quantified by measuring counts per
minute (CPM) in duplicates from each sample at the Wallac
Winspectral 1414 Liquid Scintillation Counter (PerkinElmer,
MA). Samples were diluted in Pico-Fluor 40 (PerkinElmer).
Transfection of HEK-293 cells
HEK-293 cells were cultured in DMEM supplemented with
10% fetal calf serum, 100 U/ml penicillin, 1% non-essential
amino acids, and maintained in a 37uC, 5% CO2 humidified
incubator. The HEK-293 cells were transfected with HA-tagged
syndecan-4 full length, syndecan-4 S179A, syndecan-4 S179E,
His-tagged CnAa cloned into pcDNA 3.1/myc-HIS-A (custom
made, Genscript Corporation, Piscataway, NJ) using Lipofecta-
mine 2000 as instructed by the manufacturer (Invitrogen,
Carlsbad, CA). After 24 h total lysate (IP-buffer or lysis buffer),
or cytoplasmic, nuclear and membrane protein fractions were
harvested according to the protocol of the Compartmental Protein
Extraction Kit (2145, Chemicon/Millipore, Billerica, MA), and
analyzed by immunoblotting.
Pull-down experiments
Biotinylated peptides (5 mM) were incubated in total heart
extract (whole tissue lysate B) from WT mice overnight at 4uC.
Monoclonal anti-biotin-conjugated beads were added for 60 min
before the bead pellet was washed once for 10 min in IP-buffer,
four times 10 min in IP-buffer with high salt (1 M) and finally once
for 10 min in IP-buffer. To analyse for a direct interaction,
biotinylated peptides (10 mM) were incubated with 10 mg/ml
recombinant His-TF-CnA (custom made from Genscript Corpo-
ration, Piscataway, NJ) in a 100 ml binding buffer (10 mM NaCl,
20 mM Tris/HCl, pH 8, 6 mM MgCl2, 0,1% Triton X-100)
containing 1% BSA with gentle rocking for 3 h at 4uC. Twenty
five ml monoclonal anti-biotin-agarose (A-1559, Sigma, Saint
Louis, MO) was added and incubated with gentle rocking
overnight at 4uC. After collection by centrifugation, the beads
were washed three times with 1 ml binding buffer. Bound proteins
were extracted and boiled with 50 ml 26 SDS sample buffer for
five min before analysis by immunoblotting.
Overlays
CnA overlays were conducted using active recombinant protein
expressed in E. coli (# 14-446, Upstate, Lake Placid, NY), native
CnA purified from bovine (# 14-390, Upstate) or endogenous
CnA in heart extract. Syndecan-4 overlays were conducted using a
biotin-syndecan-4 (171–198) peptide. Peptide arrays consisting of
either the cytoplasmic part of syndecan-4 or the whole of CnA
synthesized as partly overlapping 20-mer peptides (Biotechnology
Centre, Oslo, Norway) were first blocked in 5% non-fat dry milk
or 1% casein in Tris-Buffered Saline Tween 20 (TBST) for 2 h at
room temperature. The overlays were performed by incubating
overnight at 4uC and then washing the membrane 5 times in cold
phosphate-buffered saline with Tween 20 for 5 min at 4uC. These
were overlayed with CnA (active recombinant protein (Upstate,
Lake Placid, NY), native bovine CnA (Upstate) or endogenous
CnA from LV extract) or a biotin-syndecan-4 peptide, respective-
ly. Bound CnA or syndecan-4 was detected by immunoblotting.
Immunoblot analysis
Cell and tissue extracts and immunoprecipitates were analyzed
on 6%, 7.5%, 10%, 15% or 4–20% SDS/PAGE and blotted onto
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PVDF membranes. The PVDF membranes and peptide arrays
were blocked in 5% non-fat dry milk or 1% casein in TBST for
60 min at room temperature, incubated for 1–2 h at room
temperature or overnight at 4uC with primary antibodies, washed
five times five min in TBST and incubated with a horseradish-
peroxidase-conjugated secondary antibody. Blots were developed
by using ECL Plus (GE HealthCare, RPN2132). The chemilumi-
nescence signals were detected by Las-1000 or Las-4000 (both
Fujifilm, Tokyo, Japan). Actin, GAPDH or Coomassie Brilliant
Blue (Bio-Rad, R-250) was used as loading control.
Antibodies
Immunoblotting and immunoprecipitation were carried out
using anti-GSK-3b (1:1000 dilution, #9315, 27C10), anti-pGSK-
3b (1:1000 dilution, #9336, Ser9), Sapk/JNK (1:500 dilution,
#9252), anti-pSAPK/JNK (1:500 dilution, #9251, Thr183/
Tyr185), anti-p38 MAPK (1:500 dilution, #9212), anti-pp38
MAPK (1:500 dilution, #9211, Thr180/Tyr182) all from Cell
Signaling Technology, Danvers, MA, anti-D-Heparan Sulfate
(3G10 epitope, 1:1500 dilution,#370260, Seikagaku Corporation,
Tokyo, Japan), anti-syndecan-4 (1:200 dilution, sc-15350, used for
coimmunoprecipitation as epitope mapping demonstrated recog-
nition of amino acid sequence located to N-terminus of syndecan-4
(Fig. S3A)), anti-pS179-syndecan-4 (1:200 dilution, sc-22252-R),
anti-calcineurin A (1:200 dilution, sc-6124) all from Santa Cruz,
CA, anti-syndecan-4 (1:2000, #1420, a kind gift from A.
Horowitz, Angiogenesis Research Center and Section of Cardi-
ology, Dartmouth Medical School, Lebanon, NH and J. Li,
Division of Cardiology, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA, epitope mapping demon-
strated specific recognition of amino acid sequence located to the
V-region in syndecan-4 (Fig. S3B)), anti-pS179-syndecan-4-HRP
(1:2000, #41144, custom made, Genscript Corporation, Piscat-
away, NJ), anti-EGFR (1:500, sc-03, Santa Cruz) anti-actin (1:500
dilution, sc-8432, Santa Cruz), anti-calsequestrin (1:2500 dilution,
PA1-913, Affinity BioReagents, Golden, CO) anti-PKC-a (1:200
dilution, sc-208, Santa Cruz, CA), anti-CaM (1:200, C7055,
Sigma), anti-pNFATc4 (1:200 dilution, sc-32630-R), anti-NFATc4
(1:200 dilution, sc-13036), anti-GAPDH (1:500 dilution, sc-20357),
anti-histone H4 (1:500 dilution, sc-8658) all from Santa Cruz, anti-
collagen type I (1:750 dilution, #1310-01, Southern Biotech,
Birmingham, AL), anti-collagen type III (1:3000 dilution, #600-
401-105, Rockland Immunochem., Gilbertsville, PA), anti-colla-
gen type VIII (1:500 dilution, #LC-C46861, LifeSpan Bioscienc-
es, Seattle, WA), anti-biotin-HRP (1:2500 dilution, A-0185) and
anti-biotin-conjugated beads (A-1559) both from Sigma. Horse-
radish peroxidase-conjugated anti-mouse (1:2500 dilution,
NA931V), donkey anti-rabbit IgG HRP affinity purified polyclon-
al antibody (1:2500 dilution, NA934V) both from GE HealthCare
and anti-goat IgGs (1:2500 dilution, HAF109, R&D Systems,
Minneapolis, MI) were used as secondary antibodies.
Peptide synthesis
Peptide arrays were synthesized on cellulose paper using a
Multipep automated peptide synthesizer (INTAVIS Bioanalytical
Instruments AG, Koeln, Germany) as described [50]. Arginine
coupled peptides were synthesized and purified to 95% purity
(Genscript Corp, Piscataway, NJ) [51]. Biotinylated peptides were
purified to 55–95% purity (Genscript Corporation or Biotechnol-




















Densitometric analysis was performed using Image Gauge 3.46,
Science lab 99 (Fujifilm, Tokyo, Japan), Image Quant (Fujifilm),
Scion Image (Scion Corporation, Frederick, Maryland) or ImageJ
(NIH).
Equipment and settings used for obtaining and
processing images
All figure layouts were made using Photoshop CS2 or CS3
(Adobe Systems Inc., San Jose, CA). Cropping of images was
carried out, and labeling and molecular size markers were added.
When electrophoretic blots were cropped, care was taken to retain
important bands, and at least six band widths above and below the
band of interest where possible. Occasionally, brightness and
contrast was adjusted equally across the entire image, including
controls, in Image Gauge or Photoshop CS2 or CS3.
Statistics
Data are expressed as group mean 6 s.e.m. and analyzed in
Statistica 6.0 or GraphPad Prism 5.0. All data were tested for
normality before comparisons between groups were made. All in
vivo and PCR data were examined using one-way ANOVA with
adjustment for multiple comparisons using the method of Hothorn
et al. [52]. Western data were analyzed using paired or unpaired
two-tailed Students t-test, or ANOVA with subsequent Newman-
Keuls or Bonferroni post hoc test. Differences were considered
significant for p,0.05.
Supporting Information
Figure S1 Activation of calcineurin-dependent nuclear factor of
activated T-cell (NFAT) signaling in cardiomyocytes in response to
cyclic mechanical stretch. (A) Relative NFAT luciferase activity in
neonatal cardiomyocytes from NFAT-luciferase reporter mice
subjected to cyclic mechanical stretch (MS) (10%, 1 Hz) for
10 min–24 hours (n = 6–19). (B) Relative NFAT luciferase activity
in neonatal cardiomyocytes from NFAT-luciferase reporter mice
subjected to 24 hrs of cyclic mechanical stretch with and without
the calcineurin-inhibitor cyclosporin A (CsA) (n = 8–19).Vehicle
(Veh) served as control. Values are mean 6 s.e.m.
(PDF)
Figure S2 Activation of nuclear factor of activated T-cell
(NFAT)-interacting, pro-hypertrophic signaling pathways in wild
type (WT) and syndecan-42/2 (Syn-42/2) mice in response to
pressure overload induced by aortic banding (AB). Representative
immunoblots and relative quantity of (A) calcineurin (CnA), (B)
glycogen synthase kinase (GSK)3-b and phosphorylated GSK3-b
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(pGSK3-b), (C–D) Akt and phosphorylated Akt (pAKT), (E–F) c-
jun N-terminal kinases (JNK)2/3 and phosphorylated JNK2/3
(pJNK2/3), (G–H) extracellular signal regulated protein kinase
(ERK)1/2 and phosphorylated ERK1/2 (p ERK1/2) and (I–J)
p38 and phosphorylated p38 (pp38) in left ventricles (LV) from
WT and Syn-42/2 mice 24 h after AB or sham operation (SHAB)
(n = 5–6). A calcineurin- rich cell lysate (Ramos) was used as
control for the calcineurin-positive protein band. Vinculin and
GAPDH were used as loading control. Values are mean 6 s.e.m.
(PDF)
Figure S3 Epitope mapping of syndecan-4 antibodies. Synde-
can-4 residues important for antibody binding were identified by
overlaying an array of immobilized syndecan-4 20-mer peptides
with (A) anti-syndecan-4, (sc-15350), (B) anti-syndecan-4 (#1420),
(C) anti-pS179-syndecan-4 (sc-22252-R) or (D) anti-pS179-synde-
can-4-HRP (# 41144). Underlined and bold amino acids indicate
the core epitope. (A) Anti-syndecan-4 (sc-15350) recognized the
amino acid sequence SIRETEVIDPQDLLEGRYFSGALPDD
located to the N-terminus of syndecan-4 consistent with the
source information from the producer (Santa Cruz) (n = 1). (B)
Anti-syndecan-4 ( #1420) strongly and specifically recognized the
amino acid sequence KDEGSYDLGKKPIYKKAPTNEFYA
located to the cytoplasmic part of syndecan-4. Further mapping
revealed that the core epitope was located to the V-region in
syndecan-4 (underlined sequence in B) (n = 3). Both pS179-
syndecan-4 antibodies (sc-22252-R, (n = 2) and #41144 (n= 3))
recognized pS179-syndecan-4 strongly (right panels in C and D,
respectively) compared to the non-phosphorylated syndecan-4 (left
panels). Consistent with our findings and according to Genscript,
the #41144 antibody is 32 times more specific for pS179-
syndecan-4 than non-phosphorylated syndecan-4.
(PDF)
Table S1 Animal characteristics, heart rates, left ventricular
pressures and echocardiographic measurements.
(DOC)
Table S2 Myocardial structure and neurohormonal changes.
(DOC)
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  WT Syn-4-/-   WT Syn-4-/-   WT Syn-4-/- 
Characteristics 





BW, g 21.8 ± 1.3 21.9 ± 1.1 
 
23.7 ± 0.9 25.0± 0.9 
 
25.7 ± 1.2 21.3 ± 0.9* 
TL, mm 15.9 ± 0.1 17.3 ± 0.1* 
 
16.6 ± 0.2 17.4 ± 0.1* 
 
17.1 ± 0.2 17.5 ± 0.1 
LVW/TL, mg/mm 4.45 ± 0.17 4.55 ± 0.17 
 
4.78 ± 0.15 4.84 ± 0.24 
 
7.77 ± 0.28§ 8.19 ± 0.22§ 
RVW/TL, mg/mm 1.15± 0.09 1.10 ± 0.07 
 
1.22 ± 0.03 1.19 ± 0.05 
 
1.63 ± 0.12§ 1.98 ± 0.12*§ 
LW/TL, mg/mm 8.88 ± 0.27 8.49 ± 0.22 
 
8.48 ± 0.12 8.56 ± 0.18 
 








LVILDd, mm/mm  
 
0.479 ± 0.009  0.463 ± 0.008  
 
0.491 ± 0.008  0.532 ± 0.007*§  
Echo-M-mode 
  





IVSd/TL, mm/mm   0.044 ± 0.002 0.042 ± 0.002 
 
0.046 ± 0.001 0.043 ± 0.001 
 
0.063 ± 0.002§ 0.044 ± 0.002* 
IVSs/TL, mm/mm  0.056 ± 0.004 0.050 ± 0.003 
 
0.055 ± 0.001 0.055 ± 0.002 
 
0.079 ± 0.002§ 0.049 ± 0.003* 
LVDd/TL, mm/mm  0.250 ± 0.007 0.235 ± 0.006 
 
0.246 ± 0.004 0.240 ± 0.009 
 
0.243 ± 0.005 0.277 ± 0.009*§ 
LVDs/TL, mm/mm  0.202 ± 0.009 0.188 ± 0.004 
 
0.193 ± 0.006 0.189 ± 0.011 
 
0.193 ± 0.008 0.262 ± 0.012*§ 
LVFS, % 19 ± 3 24 ± 5 
 
22 ± 2 22 ± 3 
 
24 ± 2§ 8 ± 1*§ 
PWd/TL, mm/mm  0.040 ± 0.001 0.036 ± 0.002 
 
0.043 ± 0.001 0.043 ± 0.001 
 
0.062 ± 0.002§ 0.048 ± 0.003* 
PWs/TL, mm/mm  0.052 ± 0.002 0.048 ± 0.002 
 
0.057 ± 0.002 0.057 ± 0.002 
 
0.079 ± 0.003§ 0.056 ± 0.002* 
LVEF, % 40 ± 5 41 ± 2 44 ± 3 44 ± 4 44 ± 3 17 ± 2*§ 
LAD/TL, mm/mm  0.114 ± 0.006 0.103 ± 0.005 
 
0.096 ± 0.004 0.098 ± 0.003 
 
0.148 ± 0.010§ 0.176 ± 0.006*§ 
AOD/TL, mm/mm  0.093 ± 0.002 0.083 ± 0.003 
 
0.086 ± 0.002 0.087 ± 0.003 
 
0.089 ± 0.002 0.085 ± 0.002 
Echo-Doppler 
  





HR, beats/min 436 ± 16 479 ± 36 
 
457 ± 16 460 ± 21 
 
495 ± 14 488 ± 12 
 2 
AB Vmax, m/s 
  
4.3 ± 0.1 4.4 ± 0.1 
Mit PHT, ms 19.6 ± 2.5 21.3 ± 1.5 
 
20.7 ± 1.3 20.9 ± 0.9 
 
17.2 ± 0.9 16.0 ± 0.7§ 
 VTI, cm 4.05 ± 0.40 3.71 ± 0.21 
 
3.86 ± 0.28 4.37 ± 0.26 
 
3.81 ± 0.20 2.80 ± 0.22*§ 
CO, ml/min 20.87 ± 3.08 20.84 ± 2.47 
 
21.39 ± 1.83 24.69 ± 2.17 
 
24.77 ± 2.26 17.54 ± 1.55* 
Catheterization 
  
n 9 9 
  
LVSP, mmHg 95 ± 2 105 ± 4* 
LVEDP, mmHg 8.9 ± 2.0 13.1 ± 2.1 
  
LVdP/dtmax, 
mmHg/s 7818 ± 658 8843 ± 695 
  
LVdP/dtmin, 
mmHg/s 7346 ± 452  8691 ± 526 
  
SHAB, 3 week sham-AB operated group; AB, 3 week aorta banded group;  WT, wild type mice; Syn-4-/-, syndecan-4-/- mice; BW, body weight; TL, 
tibia length; LVW, left ventricular weight; RVW, right ventricular weight; LW/TL, lung weight; Echo-2D, two-dimentional echocardiography; LVILDd, 
left ventricular internal longitudinal diameter in diastole; IVSd/s, inter-ventricular septum thickness in diastole respectively systole; LVDd/s, left 
ventricular diameter in diastole respectively systole; LVFS, left ventricular fractional shortening; PWd/s, posterior wall thickness in diastole 
respectively systole; LAD, left atrial diameter; AOD, aortic diameter; HR, heart rate; AB Vmax, peak flow over aortic constriction; Mit PHT, mitral 
pressure half time; LVOT VTI, left ventricular outflow tract velocity time integral; SV, stroke volume; CO, cardiac output; LVSP, left ventricular 
systolic pressure; LVEDP, left ventricular end diastolic pressure; LVdP/dtmax, maximum rate of  left ventricular pressure rise; LVdP/dtmin, maximum 
rate of left ventricular pressure decline; *, Syn-4-/- significantly different from WT in same group (p < 0.05); §, AB significantly different from SHAB 
in respective genotype group (p < 0.05); ); catheterization following AB was not performed as the aortic constriction was too tight to allow for 

















  WT Syn-4-/-   WT Syn-4-/- 
 
n 102 112 
 
120 134 
Cardiomyocyte width, μm 14.5 ± 0.3 13.7 ± 0.2 
 
18.4 ± 0.7§  14.3 ± 0.3* 
Cardiomyocyte length, μm 103.2 ± 1.8 101.6 ± 1.6 
 
 111.6 ± 2.0§ 111.5 ± 1.8§ 
 
n 10 9 
 
10 10 
Collagen type I, %  100.0 ± 12.3  112.9 ± 18.2 
 
95.4 ± 9.2 82.5 ± 12.9 
Collagen type III, %  100.0 ± 6.6  85.2 ± 9.5 
 
 173.0 ± 11.1§  173.7 ± 11.5§ 
Collagen type VIII, %  100.0 ± 6.7  95.4 ± 5.0 
 
142.1 ± 9.7§ 133.4 ± 10.7§ 
 
n 7 8 
 
9 12 
LV water content, mg  68.6 ± 1.9 64.4 ± 4.8 
 
 103.4 ± 6.6§  113.4 ± 3.4§* 
n 7 6 7 7 
Angiotensin II, pg/ml 700 ± 27 668 ± 36 642 ± 23§ 958 ± 19§* 
SHAB, 3 week sham-AB operated group; AB, 3 week aorta banded group;  WT, wild type mice; Syn-4-/-, 
syndecan-4-/- mice; LV, left ventricle; Collagen assessed by Western blot, values relative to WT-SHAB. *, Syn-4-/- 
significantly different from WT in same group (p < 0.05); §, AB significantly different from SHAB in respective 
genotype group (p < 0.05); Values are mean ± s.e.m. 
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